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Phytoecdysteroids have  anabolic effects in humans and especially popular among athletes as sport 
performance enhancers. This study investigated the metabolism of an ecdysteroid, 20-Hydroxyecdysone 
(20HE), and its physiological effects, at concentrations not expected to be anabolic.  
The uPA (+/+)-SCID chimeric mice were administered 20HE. An excretion study was conducted on a male 
volunteer, after administration of low and high doses of supplement-derived 20HE. The effect of a 20HE 
containing supplement for two months was recorded in male athletes, with samples before and after 
consuming a 20HE supplement (n=4) or placebo (n=4). The detection of urinary 20HE was determined. 
Anthropometric changes were measured, as well as glucose, lipids and haematology, and an index of aerobic 
fitness (VO2 max). The hepatic transcriptome and proteome were analysed in RNA and protein extracted from 
the SCID mice treated with 20HE. Effects on Mitochondrial Membrane Potential (MMP) were tested in-vitro 
in human skeletal muscle cells and adipocytes treated with 20HE (5 and 10µM).  
Fifteen drug metabolizing genes were overexpressed, including NOS3, and, 29 were under expressed, 
including CYP17A1, in the 20HE treated group. In mice, following multiple doses, 20HE was detectable for up 
to 24h. In a human subject, following a high dose of supplement-derived 20HE, the ecdysteroid was first 
detected after 2 hours, with peak detection between 4-5 hours, and remained detectable for up to 48 hours. 
The lower concentration was only detectable for 36 hours. 20HE supplement decreased diastolic blood 
pressure (p=0.05), with no significant changes in muscle mass and aerobic fitness. Seventy proteins were only 
detected in the 20HE group, while 37 genes were significantly differentially expressed. Upregulation of NOS3 
was a consistent finding, and, validated at both the protein and RNA levels in human endothelial cells.  
Low dose, supplement-derived 20HE was detectable in human urine for at least 36 hours, and its 
administration (2 months) was not anabolic, but, was still able to alter systemic blood pressure and the 
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1.1 Nutraceuticals. Nutraceuticals, a term first coined in the late 1980s by De Felice, combined both 
‘nutrition’ and ‘pharmaceutical’, to describe the use of food as medicine (1). This practice dates back to ancient 
civilizations of the Nile and Indus Valley to current day. Nutraceuticals are food-derived products claiming 
added benefits on health, common amongst them being prevention of diseases and delaying the aging 
process, as well as other physiological benefits (2). Nutraceuticals are subdivided into functional foods and 
dietary supplements. Functional foods are basically foods that contain a component that exert at least one 
function on the body (3). This includes the artificial fortification of foods with vitamins or minerals during 
processing, most common of these being enriched flour, Vitamin D fortified milk, iodized table salt and calcium 
fortified orange juice. Dietary supplements is the other major class of nutraceuticals (4). While dietary 
supplements can be recommended by physicians, in the form of capsules or injections, they are not drugs. 
Unlike supplements, drugs have to be nationally/internationally certified and for this they undergo rigorous 
monitoring. The selection of drugs involves difficult, lengthy and capital-intensive discovery and development 
processes. Most times these are also inefficient since it’s been reported that 95% of potential drugs fail in the 
development phase due to poor performance during their testing of their Absorption, Distribution, 
Metabolism and Excretion (ADME) (5). In addition to ADME, liberation and toxicity are also sometimes 
considered as part of the criteria by which New Chemical Entities (NCEs) are investigated. Criteria of NCE 
investigation aim to determine their kinetics and dynamics, target organ exposure, time profiles within a 
biological system, whether in animals or humans, to establish its efficacy, safety, potency and bioavailability, 
to become a potential drug (6). After undergoing in-silico pharmacokinetic studies, these compounds can be 
considered for multiple pre-clinical and clinical trials, after filing for regulatory status, through agencies like 
the Food and Drug Association (FDA). After this extensive and expensive journey, many drugs do not even 
make it into the market due to other limiting factors within the biological systems including SNPs and 
environmental factors (6).  None of these tests and certification are required of supplements, as they are 
defined as ‘over-the-counter drugs’. 
 
Dietary supplements are considered additives to one’s diet, intended to compensate for essential 
micronutrients that may be missing or consumed in insufficient amounts (4). The FDA legally defines dietary 
supplements as orally ingested, dietary ingredients that include vitamins, minerals, amino acids and 
herbs/botanicals, in addition to other substances taken for the purpose of supplementation of diet (7). These 
supplements are available in many forms making them appealing to a large proportion of the population, and 
include tablets, capsules, powders, energy bars, liquids and candy-like gummies (8).  Terms like ‘organic’ and 
‘natural/all natural’ products and increased public interest in improving and maintaining health have 
contributed to the reported increase in the consumption of these products, with some 49% of adults taking 
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dietary supplements, as per data between 2007 to 2010 (8). The main reasons for this consumption were cited 
as being to improve overall health and maintaining health, in percentages of 45% and 33% respectively. 
Consumer awareness of preventative healthcare, with a rising geriatric population and growing prevalence of 
chronic diseases, along with the busier daily schedule of modern life, have promoted the wish for efficient, 
updated approaches to nutrition (4), which have resulted in additional growth in the variety and sale of dietary 
supplements. It is currently estimated that the global dietary supplement market is almost $133 billion and 
continues to grow at a compound annual growth rate (CAGR) of 8.8%, estimated to reach more than $278 
billion by 2024, according to the financial information platform marketwatch.com (9). Conversely, this may be 
hindered by negative publicity related to fake products. As these dietary supplements are not FDA regulated 
in most countries, but, rely on the assurance of manufacturers for their products’ safety and effectiveness, 
this is basically an ‘honour system’ (10).  Negative publicity  included cases such as the death of a healthy 
student in the USA due to acute cardiac arrhythmia from an unintentional overdose of caffeine supplement 
powder (10). This is an example of a ‘natural’ and ‘organic’ everyday ingredient that actually caused serious 
negative effects at very large doses. While clinical trials and validated analytical methods are ideal to establish 
efficacy, these are not requirements for dietary supplements and yet remain advocated and recommended. 
In the USA, unlike for prescription drugs, dietary supplements, even those recommended by physicians to 
patients to compensate for any deficiency, are only presumed safe, unless reported otherwise by end-users 
or physicians to the FDA (10). Only after such reported adverse effect(s) is a case for this specific dietary 
supplement or its ingredient put under series of processes, from mitigation plans to warning and announcing 
to the public about these safety concerns and finally removal from the market (10). While the FDA requires 
dietary supplements’ manufacturers to report any advert effects of their supplements, it appears that less 
than 1% of these serious effects get reported to the FDA (10).  
 
1.2 Testing of Supplements. According to a metanalysis, based on 150 prevalence studies of dietary 
supplements among athletes, it was reported that elite athletes consume more dietary supplements than 
recreational athletes (11). This gave rise to the issue of ensuring the safety of dietary supplements, with third 
party testing of supplements being initiated. The National Sanitation Foundation (NSF), founded in the USA in 
1944, was set up to ensure consumer safety. It is currently branded as NSF International and tests dietary 
supplements according to three reviewing criteria: label claim, toxicology and contaminants (12). In the UK 
the LGC Group provides a similar function. LGC was set up as the Laboratory of the Board of Excise in 1842 to 
test for adulteration in tobacco and regulate its production. The company still acts as the Government 
Chemist, providing expert opinion through independent chemical and bioanalytical testing. LGC Standards, a 
division of LGC Group, is the National Measurement Institute of the UK. Other, for profit testing services also 
emerged, such as consumerlab.com, which offered informational and quality certification in the USA, Canada 
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and China. A monitoring program was set up by the FDA on dietary supplements claiming weight loss or 
increased muscle growth being sold online and have led to them being taken off store shelves (10). That is 
because most of these products, instead of containing the ingredients declared on the label, are actually 
adulterated with prescription drugs that may have major adverse effects, including drug-drug interactions, 
causing serious pathology, including hepatic or cardiac toxicity (10).   
 
The NSF has specific standards for certification of sports supplements to protect athletes from contaminants 
that might contain, but not declared on the label. This is especially important when considering compounds 
that are banned by athletic organisations, as well as some governments, such as anabolic androgenic steroids 
(AAS) and narcotics (12). AAS use was banned legally in 1990 in the USA under schedule III-controlled 
substance offense punishable by 5 and up to 10 years’ imprisonment (13).  Other countries followed, including 
Sweden in 1991, Norway in 2013, as well as the UK, Australia, Argentina, Brazil, Portugal and Saudi Arabia (14).  
Though AAS is banned in these countries, easy access is granted by the internet (14), as per the findings of an 
official investigation of the U.S Government Accountability Office (GAO) on the purchase of anabolic steroids 
without prescriptions, they were easily obtained without prescription using the internet (13). In this 
investigation 22 orders were placed and only 14 shipments were received, 10 were from foreign countries 
(Italy, China & Greece) and 4 were from within the USA and notably, none of these 4 contained AAS as 


















It was reported that the highest rates of use of AAS were in the countries of the Middle East and South 
America, and its use highest among recreational athletes (14).  Amongst recreational athletes, bodybuilders 
are the most likely to use a combination of different substances including proteins, pills and amino acids 
(Figure-1) (14). The strains caused by the combined excessive use of these supplements on the physiology is 
immense and long-term use of proteins as supplements, instead of protein-rich foods, can increase risk of 
osteoporosis and cause the deterioration of existing kidney problems (15). In addition, treatment fatigue has 
also been reported, which is defined as the decreased adherence to treatment due to many reasons, including 
adverse effects, inconvenient scheduling and dosage (16). This is apparent in the sport of bodybuilding, often 
‘prescribed’ a number of pills and shakes, that they expected to adhere to as part of their training. One 
example is presented in (Figure-1), where an advertised growth hormone and testosterone stimulating 
supplement’s recommended dose is 3 capsules in the morning and 4 in the evening.  
 
A study from Germany of 164 young elite athletes reported that 80% were using supplements, with 
significantly increased prevalence of use among older athletes, mainly for health-related reasons (17). The 
study also reported that only 36% of these elite athletes were familiar with the possibility of inadvertent 
doping due to contamination in these supplements purchased from pharmacies and supermarkets (17). 
Another study surveyed 77 professional swimmers in Australia and reported that 94% were consuming dietary 





(Figure-1) An example of a set of supplementations recommended to a body builder by a person identifying 
himself as a certified nutritionist\Coach. Advertised claims on the supplements include: Growth hormone 
and testosterone stimulant capsules (a) and antiaging, cardiac strengthening, muscle mass increasing and fat 
burning & converting to energy powder (h). Other supplements included branched chain amino acids, fatty 
acids, protein powders and vitamins (b-g). 
a) b) c) 
          





g)        h) 
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1.2.1 World Anti-Doping Agency (WADA). WADA was established by the international Olympic Committee 
(IOC) in 1999 for the promotion and coordination of the fight against doping in sport. As part of its role WADA 
accredited several laboratories to test for the substances that are classified as dopants. Laboratories that are 
WADA accredited for testing of prohibited substances in sport go through an extensive and rigorous process 
to obtain this accreditation. This starts with expression of interest to setting up the analytical methods, 
application of them in a standardized manner and acquiring ISO/IEC 17025 accreditation (19). Currently there 
are 30 WADA accredited labs in 27 countries worldwide.  In addition to the accredited laboratories, a list of 
prohibited substances and methods in sport is published every year by WADA that clearly states and identifies 
all substances that are banned and shall not be consumed by competing athletes in and out of competition. It 
is classified in different categories such as steroids, stimulants, manipulation or gene doping (Table-1). In 
addition to the prohibited list, WADA also publishes a monitoring list (Appendix 1), that is also updated 
annually. This list is for substances that are not prohibited, but, require monitoring for patterns of abuse by 
competing athletes. Such substances include caffeine, which is considered a food additive, dietary supplement 
and drug.  
 
The main objectives of WADA are to ensure fair play, clean competition and protection of athletes. While some 
professional athletes wilfully abuse illegal substances to gain a competitive advantage, in most cases this 
appears to be inadvertent. Examples of this are innumerable, including that of Maria Sharapova, the female 
tennis player, who tested positive in 2016. The athlete had been taking meldonium for 10 years without falling 
foul of WADA. However, meldonium was added to the WADA 2016 prohibited list, and in that year the athlete 
tested positive for it, because she failed to read the updated list (19).  
 
In 2009 WADA approved the profiling of haematological, biological variables, or biomarkers, of competing 
athletes and the Athlete Biological Passport (ABP) was developed to monitor these blood biomarkers, and 
comparing it to a population. First, a baseline was created for each athlete over time, from at least 4 blood 
samples, after which any variation could indicate the effect of doping (21). ABP provides a new approach in 
the fight against doping since it is investigating the effects exerted by a prohibited substance, rather than 
investigating the presence or absence of the prohibited substance or its metabolites in the blood or urine.  
 
Recently the IOC released a statement emphasising the need for sport-specific research on supplements that 
uses appropriate research experimental models and methods, taking into account the real-life practices of 
athletes (22). A first step in the recommendation was to conduct a detailed comprehensive nutritional 
assessment of the athlete, that included dietary evaluation, clinical examination and medical history, taking 
into consideration age, gender and ethnicity (22).  This can be viewed as an application of Diet Quality Indices, 
23 
 
which are algorithms that aid in the quantification of adequacy between nutrient intake and reference intakes 
that assures optimal health (23). A recent report suggested athlete-specific diet index ADI as an efficient tool 
for the assessment of athlete’s quality of diet and to provide guided support of nutrition intervention (24).  All 
athletes recruited in the study reported ADI as relevant and easy, which is a good marker for compliance and 





















S1 Anabolic agents Epitestosterone; 
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M3 Gene and cell 
doping 
Use of nucleic 
acid that alter 
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sequence 
S3 Beta-2 agonists Formoterol; 
Indacaterol 
P1 BETA-BLOCKERS This class is 
specific to few 
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S6 Stimulants Amfetamine; 
Benzfetamine; 
S7 Narcotics Buprenorphine; 
Diamorphine 
(heroin) 
S8 Cannabinoids Cannabidiol. S9 Glucocorticoids Cortisone; 
Deflazacort 




1.3 Sport performance enhancers. Mediators of sporting performance and exercise have become the focus 
of much research, both, from the competitive and health points of view. Swiftly following on from this has 
been the search for compounds that could act as exercise mimetics and enhancers of sporting performance, 
often effecting changes in body composition and energy metabolism, at least in part, mediated by alterations 
in mitochondrial and vascular functions (11). The most prevalent families of compounds that fall under these 
criteria are the anabolic androgenic steroids (AAS), such as testosterone analogues, and stimulants, such as 
caffeine and amphetamines (7). These are often components of many marketed dietary supplements (9). 
However, as both AAS and many stimulants are either prescription only drugs or prohibited substances in 
sporting competition, legal and easily obtainable substitutes for these are vigorously sought (25).  
 
Amphetamines are perhaps the most widely abused drug in baseball in USA and are especially popular 
amongst young athletes (26). Erythropoietin is another substance with a proven track record of abuse, highly 
effective as an aerobic enhancer and has been linked to many deaths of athletes in cycling and other 
endurance sports (27,28). Caffeine is a widely consumed, socially acceptable beverage, forming part of the 
diet of a large proportion of the adult population. There is clear evidence showing caffeine to be an ergogenic 
aid in several types of sport (29). Even relatively moderate intakes of caffeine (≈3 mg/kg body mass) can 
improve performance of a range of sporting disciplines including endurance sport, stop-and-go events and 
high intensity sport (30-33). It is freely available from online outlets in formulations promoted as a natural 
enhancer of performance during exercise, mostly for ergogenic effects among adolescents (10). It was 
reported that some of these caffeine formulations contain up to 30 times the lethal dose of caffeine (10).  
 
AAS are one of the most popular doping substances. They are synthetic derivatives of the male hormone 
testosterone. They have significant effects on human physiology that are beneficial for athletic performance 
(34). Their use, both as sport performance enhancers and for improving body shape, by increasing muscle, 
was first reported in the 1950s and rapidly spread amongst athletes, despite being denounced by physicians 
(35). It has been shown that short-term administration of AAS to athletes increased strength and bodyweight 
(36). Strength gains of up to 20% of baseline strength and up to 5 kg bodyweight, that may be attributed to an 
increase of the lean body mass, have been reported (37). A reduction of fat mass has been shown by some 
studies but this is not a consistent finding (38). AAS affects erythropoiesis, through the stimulation of 
erythropoietin synthesis and red cell production and blood haemoglobin levels, but whether this improves 
endurance performance is still unclear (39). The effects of AAS on metabolic responses during exercise training 




AAS act principally via the androgen receptors, with involvement of some other mechanisms of action, 
dependent on variations in the steroid molecule and receptor affinity (40). Other mechanisms include the 
effects of the enzymes 5-alpha-reductase and aromatase (41). 5-alpha-reductase has an important role in 
converting AAS into dihydrotestosterone (androstanolone), which then acts in the cell nucleus of target 
organs. Aromatase converts AAS to oestradiol and oestrone, antagonistic action to oestrogens and a 
competitive antagonism to the glucocorticoid receptors. AAS-induced increment of muscle tissue is attributed 
to hypertrophy and the formation of new muscle fibres, in which key roles are played by the androgen 
receptors (42). 
 
The main adverse effects of acute and chronic AAS abuse are increased sexual drive, acne vulgaris, hirsutism 
and propensity for aggressive behaviour (43). AAS administration inhibits endogenous production of 
testosterone and gonadotrophins, an effect that persists for months after drug withdrawal. Worsening of 
cardiovascular risk factors following AAS, such as elevated blood pressure, increased triglycerides and lowered 
HDL-cholesterol have been reported (44). In male athletes AAS did not seem to affect cardiac structure and 
function, though in murine studies these drugs have deleterious effects on heart structure and function (45). 
The effects of AAS on the cardiovascular system are proposed to be mediated by the occurrence of 
atherosclerosis, perhaps due to the dyslipidaemia, thrombosis, vasospasm or direct injury to vessel walls, or a 
combination of these (46). Psychological effects, leading to abnormal and anti-social behaviour, are strongly 
associated with AAS abuse, apparently increasing aggression and hostility. Depression also seem to be related 
to dose and drug dependence, though only reported in a small number of AAS users (47). Many other adverse 
effects have been associated with AAS misuse, including disturbance of endocrine and immune function, 
alterations of sebaceous system and skin, changes of haemostatic system and urogenital tract. It is also 
possible that these adverse effects are an underestimate because of the relatively low doses administered in 
most studies, as for ethical reasons studies do not approximate doses used by illicit steroid users (48).  
 
Apart from the endogenous AAS, these steroids can be synthesized, in order to evade doping control tests. 
This was first discovered in 2003 with the discovery of the designer steroid tetrahydrogestrinone (49,50). 
Despite much effort and research the detection of these ever increasing list of designer steroids this still 
remains one of the main analytical challenges in the doping control field. Other potential performance 







1.4 Ecdysteroids. Plant steroids were classified into 7 groups according to Kreis and Müller-Uri (2010) 
depending on their function or chemical structures (51). These plant steroids groups include: Phytosterols; 
campesterol and stigmasterol, Brassinosteroids; Brassinolide, castasterone and Phytoecdysteroids; 20-
Hydroxyecdysone (20HE), which is the substance of interest in this study (51). Phytoecdysteroids, and mainly 
20HE, have had a revived interest in their uses as potential aids to weight loss and sport performance 
enhancement especially among recreational and elite athletes. Ecdysteroids are polyhydroxylated 
ketosteroids that were initially isolated from arthropods, with a role in the moulting process (52) 
Phytoecdysteroids, have subsequently shown to be more abundant in plants, with, as yet, unidentified 
hormonal functions (53). However, this family of phytosteroids have gained interest because of their 
purported anabolic effects in mammals. They are especially popular among recreational and elite athletes who 
consume these, either in their pure forms or formulated as a component of dietary supplements, as sport 




























(Figure-2) Supplements claiming to contain ecdysteroids available online. Animal Stack (a), Natural sterol 




1.4.1. Origin, biosynthesis and diversity amongst species. Ecdysteroids are polyhydroxylated ketosteroids 
that were initially isolated in insects where they regulate moulting and reproduction (52). Closely related 
molecules to ecdysteroids have been found in plants, called phytoecdysteroids, where their role is as yet 
unclear (53). 
However, their (phytoecdysteroids) possible use as pesticides has been of some interest, as they have the 
ability to interfere with insect development and reproduction and cause premature metamorphosis (56). But 
the chemical complexity of ecdysteroids and the environmental and metabolic burden of insects has made 
this research slow. A live database of all reported ecdysteroids is maintained by the University of Exeter 
(ecdybase.org), which currently lists more than 500 of them (57).  
 
Chemically, phytoecdysteroids comprise a family of compounds called triterpenoids, which includes saponins, 
phytosterols and the phytoecdysteroids (58). Plants are able to completely synthesize ecdysteroids from 
mevalonic acid and cholesterol (59). Further hydroxylations at positions C2, C20, C22, and C25 produce the 
most reported of the species, 20 hydroxyecdysone (20HE;60). The site of biosynthesis of phytoecdysteroids 
within the plant appears quite wide spread. Only a minority, about 6%, of all plant species produce 
phytoecdysteroids (61). However, some species, such as spinach and quinoa have significantly elevated levels 
of phytoecdysteroids (62).  Despite the name, ecdysteroids, insects are not able to carry out de novo synthesis 
of these steroids but need to consume phytosterols and then convert these to ecdysteroids (60). The sterol 
structure is modified to produce ecdysteroids. The major difference in the structure between these and the 

































(Figure-3) Chemical structure of ecdysteroids and mammalian steroid hormones. The top panels show some 
of the common ecdysteroids with the polyhydroxylated side chain circled in red a) 20 Hydroxyecdysteroid  b) 
Turkesterone and c) Ecdysone. The bottom panels show the mammalian steroid hormones, testosterone d) 
and 17-β oestradiol e) (60).   
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1.4.2 Effect on sport performance and health. It has been reported that dietary supplement consumption 
among professional and recreational athletes is between 40 to 88% (63), with an increasing number of them 
containing ecdysteroids. This is because ecdysteroids are widely marketed as natural anabolic agents based 
on some data from both murine and human studies. Their anabolic effect is reported to be comparable to, 
and possibly even greater than, many AAS.  Studies on rodent models revealed elevated muscle fibre size in 
groups treated with ecdysteroids, in comparison to placebo, through increased protein biosynthesis. However, 
their ability to elevate protein biosynthesis does not appear to be targeted and has also been noted to lead to 
hypertrophy of other organs, such as heart and liver (54). The first of such reports showed enlargement of 
the liver in mice. This raises the question of their safety and possible adverse effects on health. Reports 
indicate that Turkesterone is the most potent anabolic ecdysteroid, however, 20-hydroxyecdysone is the most 
studied, possibly due to its higher availability synthetically in supplements (56), and also in many ‘super’ foods, 
such as quinoa. Quinoa (Chenopodium quinoa) is a pseudo-cereal which was consumed by Native Americans 
for a long time but has recently been rediscovered by the food industry due to its protein quality, as well as a 
source of minerals, vitamins and flavonoids (64). Quinoa contains high levels of phytoecdysteroids and there 
is some evidence of it having anabolic effects. In addition to the anabolic effects, some studies have reported 
that 20-hydroxyecdysone plays a role in the control of glucose homeostasis and more possibly in the 
prevention of diet-induced obesity in mice (Figure 4; 64). In rats it has been shown to lower experimentally 
induced hyperglycaemia, and in mice it enhances insulin stimulated hepatic glucose incorporation into 
glycogen, as well as glucose utilization by many other tissues. Most of these effects appear to be via 
increased insulin sensitivity (51). Further health claims include reduction in hepatic cholesterol 
biosynthesis and increased catabolism, promoting conversion to bile acids and thus reducing systemic 
cholesterol. This effect on cholesterol is thought to be the basis for their anti-atherosclerotic effects (51). 
Other health benefits include the promotion of wound healing by stimulating keratinocyte differentiation. 
Numerous studies also show some evidence for the ecdysteroids being immunomodulatory in rodents and 
humans (51). 
 
1.4.3. Toxicity and Adverse effects. The ecdysteroids tested so far appear non-toxic, with, LD50 of 6.4 g/Kg 
after intraperitoneal injection and 9 g/Kg after oral application of 20-hydroxyecdysone to mice (55). 20-
hydroxyecdysone was not embryotoxic when injected into developing chicken eggs. While available data 
from reports indicate that 20% of hepatotoxicity cases is caused by herbal and dietary supplement-induced 




















 (Figure-4) Reported effects of ecdysteroids in mammals. Ecdysteroids gained interest due to their anabolic 
effects (54,66,76) which is triggered by protein biosynthesis (54). They play a role in the control of glucose 
homeostasis where it was reported to reduce experimentally induced hyperglycaemia and enhancement of 
the incorporation of glucose into glycogen in the liver that stimulated by insulin (64). This effect correlates to 
reported increased insulin sensitivity (26). Reduction of systemic cholesterol caused by the reduction of its 
hepatic biosynthesis which form the basis of its anti-atherosclerotic effects (51). Several studies report 
immunomodulatory effects in rodents and mice and other effects include promoting wound healing triggered 




















1.4.4. Ecdysteroids receptors. Phytoecdysteroids have recently been shown to function in humans through 
the oestrogen receptor (66). Parr et al reported data from in-silico docking experiments that ecdysteroids, 
unlike AASs, bind the oestrogen receptor (ER), especially ERß, rather than androgenic receptor (AR) (66). The 
consequences of this are yet to explored, as the ER is widely expressed in tissues and its signalling is complex 
(Figure-5).  There are several distinct pathways by which oestrogens and ERs could have cell-specific effects 
on a variety of physiological endpoints including regulation of mitochondrial biogenesis and activity. 
Oestrogens regulate gene transcription by the classical genomic mechanism of binding to oestrogen receptors 
α and β (ERα and ERβ) as well as by non-genomic pathways, via plasma membrane-associated ERs that activate 
intracellular protein kinase-mediated phosphorylation signalling cascades. The most likely signalling pathways 
for ecdysteroids acting via the ER may be in the ligand independent manner, or the non-genomic pathway. 
However, this is yet to be investigated.  As oestrogens, in addition to their role as sex steroids, are important 
regulators of metabolism and impact on diseases such as obesity and insulin resistance (IR), these may also be 
affected by ecdysteroids binding to the ER. While ERα seems to have a protective role in such diseases, the 
function of ERβ is not clear. There is some data that ERβ-deficiency may protect against diet-induced IR and 
glucose intolerance, via a pathway that involves PPARγ signaling in adipose tissue (67). The identification of 
ERα and ERβ within mitochondria of various cells and tissues may especially impact on the regulation of the 
transcription factors such as Nuclear Respiratory Factor-1 (NRF-1, NRF1). NRF-1 promotes transcription of 
mitochondrial transcription factor Tfam (mtDNA maintenance factor, also called mtTFA) and then Tfam targets 
mtDNA-encoded genes. The nuclear effects of oestrogens on gene expression directly controlling 
mitochondrial biogenesis, oxygen consumption, mtDNA transcription, and apoptosis are yet to be studied. 
Overall, the many direct and indirect effects of oestrogens on mitochondrial activities is still largely 
unexplored. The effects of its activation of ER by ecdysteroids is even less investigated, especially in the cells 














(Figure-5) Oestrogen Receptor (ER) signalling. Four mechanisms through which oestrogen signals includes: 1. 
Classical ligand-dependent. This is common to all Class 1 nuclear receptors (NRs). In the absence of ligand, the 
receptor is appropriated into an inhibitory complex and is stored within nuclei of target cells. Ligand binding 
leads to an up- or down-regulation of gene transcription and followed by tissue responses. This process causes 
changes in the conformation of the ER, stimulates homodimerization, binding to specific DNA response 
elements (ERE) in cis-acting enhancers within regulatory region of genes and gene transcription. 2.Ligand 
independent. Even if E2 is not present some GFs, such as IGF-1 are able modify the receptor function and that 
of secondary signalling molecules such as cAMP, that go on to activate various kinases pathways, leading to 
phosphorylation (P) and activation of ER at ERE-containing promoters in a ligand-independent manner.3. ERE-
independent. In those genes that lack ERE-like sequence in their promoters, E2-ER complex alters transcription 
of genes containing alternative response elements, such as AP-1, through association with other DNA-bound 
transcription factors, such as Fos or Jun, that tether the activated ER to DNA, resulting in up-regulation of gene 
expression. 4. Non-genomic. In order to elicit rapid effects of E2, for example on blood vessels, the ligand 
activates a recognised membrane-associated binding site to generate rapid tissue responses, such as the 
activation of eNOS by MAPK/PI3K/Akt pathways (68). 
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1.4.5. Metabolism of ecdysteroids. Earlier studies in mice injected with significant amounts (1 mg/animal) of 
ecdysone or 20HE (55), with faecal and urinary samples analysed by RP-HPLC over 48 hr, showed the parent 
steroid excreted unchanged, as well as about 10 metabolites, with the major ones having the unsaturated 
ketone on ring B reduced. This was unlike the reduction reactions on ring A shown during the catabolism of 
vertebrate cortisol or androgens. A more recent report looking at the murine metabolism of 20-
hydroxyecdysone injected intraperitoneally (in faecal and urinary samples) showed that the primary reactions 
produce three major metabolite groups (Figure-6). Table-2 summarises all the metabolites reported in the 
various mammalian species reported to date and their stability, if known. 
The identified metabolites to date in human subjects are 2-deoxy-20 hydroxyecdysone, 2-deoxyecdysone 
(Figure-7) and 14-deoxy 20hydroxyecdysone (69,70). The structures of the former two have been reported. 
Both these studies have used only one volunteer each being administered one dose, 20 mg. Whether there 
are age, gender and ethnicity associated differences in the metabolism of ecdysteroids in humans are not 
known currently. Furthermore, the metabolic fate of other ecdysteroid species, such as Turkesterone, are also 
yet to be investigated.  Thus, there is a need for further studies to address these issues urgently in the face of 
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Up to 24h 
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1. 14-dehydroxylation 
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Girault et al. 
Kumpun et al. 
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group followed by reduction of 7-ene 
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Ramazanov et al. 










Tsitsimpikou et al. 
(69) 
20HE Yes 14-deoxy 20hydroxyecdysone Brandt et al. (70) 
 
(Table-2) Metabolites of Ecdysteroids in mammals. Reports from claves study showed 3 metabolites with one 
metabolite stable for 6 days (71). Three metabolites were reported in mice (72,63 and55) and three were 






















(Figure-6) Metabolism of injected 20-hydroxyecdysone in mice. Primary reactions producing three major 
metabolite species: a) 14-dehydroxylation; b) Complex reduction of the 7-en-6-one chromophore, and c) 
















(Figure-7) Metabolites of 20-hydroxyecdysone in human subjects. Following the administration of an oral 
dose of 20mg of 20HE to a human volunteer, 2-deoxy-20 hydroxyecdysone (a) and, 2-deoxyecdysone (b) were 





1.5. Models for the study of human hepatic steroid metabolism. Identifying whether the effects of 
various steroids/stimulants are exerted by the parent compound or its metabolites require investigation, 
ideally in humans. However, either ethical or legal considerations often make studies in humans difficult. 
Therefore, the challenge to identifying metabolites for the various AAS and other putative sport performance 
enhancing substances is the availability of an appropriate experimental model. Further, as the route, dosage 
and form of the steroids all become important considerations it has to a model that is readily available and 
reproducible. Most AAS and stimulants are taken as orally active substances, often over a period of time, and 
are predominantly metabolized by the liver. The use of the rodent model with the humanized liver may offer 
a good alternative to in vitro methods using human hepatocytes, which have been partially successful, but 
they lack the whole-body environment to generate a full complement of metabolites. 
 
1.5.1. Murine models. Reports on chimeric mice with humanized livers achieved by transplantation of human 
hepatocytes into the spleen of various mice, such as the urokinase Plasminogen Activator-Severe combined 
Immunodeficient (uPA/SCID) mice, PXB-mouse or Fah/TK-NOG are available. All these mouse models have 
been used in-vivo studies to predict drug metabolism, pharmacokinetics and efficacy in humans (74-78). The 
uPA/SCID model was developed by Ghent University and is commercially available with KMT Hepatech Inc. 
(77) (Figure-8). In this model severe combined immunodeficient SCID mice, suffering from a transgene-
induced liver disease are transplanted early after birth with primary human hepatocytes. The human 
hepatocytes integrate in the parenchyma and progressively repopulate the diseased mouse liver without 
losing their normal metabolic functions. These mice are called chimeric or "humanized" and the success of 
each mouse is measured by human albumin (hAlb) levels that correlates with human hepatocytes. It is claimed 



















(Figure-8) SCID mice with humanized liver model. Soon after birth uPA+/+ SCID mice are injected with human 
hepatocytes in the spleen. The hepatocytes migrate and repopulate the mouse liver. Human alpha-1 











1.5.2. Model Anabolic Androgenic Steroid. Methandienone (Figure-9), also marketed by Ciba as Dianabol, is 
an orally active, synthetic AAS. Daily doses have been reported as being between 20-25 mg, taken for 5 days 
per week, over a 5-week cycle. It has a half-life of 3.5 hours, with systemic peak levels being reached between 
1.5 to 3 hours after ingestion.  The primary urinary metabolite of methandienone has been shown to be 
detectable for up to 3 days, with more recent reports of the hydroxymethyl and sulphate metabolites in the 
urine for up to 19-26 days following a single oral (5mg) dose (79). Several of these metabolites are unique to 
methandienone. The metabolism of methandienone, and most other steroids that are orally administered, 
occur predominantly in the liver and excreted in the urine, hence the humanized liver SCID mice model may 
aid in the identification of the human hepatic metabolites from orally administered drugs.  
 
As the metabolism of methandienone is so well documented it will be used as a model AAS to test the 
reproducibility and sensitivity of the chosen humanised murine model prior to embarking on studies on the 










(Figure-9) chemical structure of Methandienone; a gold standard doping agent widely used among Russian 





1.6. Target organs of ecdysteroids.  
Dietary intake and physical activity are key modulators of energy balance. The major peripheral tissues that 
dynamically participate in this are the adipose tissue and the skeletal muscle (80). Further, when considering 
sporting performance and factors that mediate this, the same tissues are likely to be salient targets.  Exercise 
and training induce the mobilisation of fat mass, and specifically the breakdown of stored triglycerides and 
the release of free fatty acids (FFAs; 81). These FFAs act as fuel for the contracting skeletal muscle during 
exercise (82). The accumulation and depletion of fat in the adipose tissue impacts on mitochondrial and 
vascular activity, and factors that mediate this process are likely to impact on sporting performance (83). This 
is supported by intervention studies that shows the reduction of fat, and the build-up of lean (muscle), mass, 
in response to training and exercise (84). Adding ecdysteroids to this inter-organ crosstalk has yet to be 
investigated, especially considering that they are now proposed to be signalling via the ER. The role of 
mitochondria on these cell types of energetically active cells, adipocytes and skeletal muscle cells, has been 




1.7. Rationale for the study.  
Despite the claims of ecdysteoirds, and mainly 20HE, having various beneficial effects on health and sport 
performance much of this is unproven, especially in humans, either in-vitro or in-vivo. Further, data on the 
metabolism of these compounds is also sparse, and the potential effect of the generated metabolites in 
mammals is unclear. Therefore, firstly, in order to even begin to understand their effects on humans, the 
metabolites of some of the most common of these ecdysteroids need to be investigated. Secondly, the effect 
of the ecdysteroids in humans is imperative especially since 20HE was added to the WADA monitoring list in 
October 2019 (Appendix 1). In order to investigate 20HE the following hypotheses were tested. 
 
1.7.1 Hypotheses 
1. 120HE can be detected in urine following ingestion of either multiple or single doses 
2. The clearance of 20HE is associated with changes in the expression of several hepatic enzymes that 
regulate Phase 1 and Phase 2 metabolism. 
3. Dietary supplement-derived 20HE, at doses too low to be anabolic, induce changes of blood pressure 
and mitochondrial membrane potential 
 
1.7.2 Aims and objectives 
1. Investigation of ecdysteroid metabolites.  
a) Metabolites of methandienone.  
The first part of the current study aimed to test the reproducibility and sensitivity of a humanized 
murine model (uPA(+/+)-SCID) to generate all the reported human metabolite species of 
methandienone and to investigate whether multiple dosing increases sensitivity of detection. Changes 
in expression of hepatic drug metabolizing enzymes, in mice treated by single or multiple doses were 
also determined, along with plasma aldehyde activity, in comparison to vehicle treated animals.  
 
b) Metabolites of 20-hydroxyecdysone.  
As the above model was found to be robust and able to reproduce previous data it has been used to 
study the metabolites of 20-hydroxyecdysone. One metabolite of 20HE was detected which has been 
confirmed as per previous reports. Several other metabolites were also apparent, and these will be 




c)  Human Excretion study  
A single volunteer was recruited for the urinary excretion study of 20HE in its pure form and as 
constituent of a supplement.  
 
2. Investigation of the human physiological effects of 20HE. 
 
a) Human whole-body effects 
The hypothesis that supplement derived 20HE induced changes in body composition, blood flow and 
aerobic fitness was tested in human volunteers. 
b) Effects of 20HE in in-vitro models 
 Effects of 20HE on mitochondrial function was studied utilising human preadipocytes and myoblasts. 
C) An omics approach exploring the effects of 20HE on expression at the genes and proteins levels.  
 


























(Figure-10) Schematic diagram representing the overall flow of the study. The project investigated two aims 
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Kits and reagents facilitating all studies were obtained from different vendors. Reagents and compounds used 
included: methanol, sodium hydrogen carbonate, potassium carbonate, RIPA buffer, acetic acid, ammonium 
bicarbonate, carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP), sodium hydroxide (NaOH), 
chloroform, isopropanol, sodium citrate, HEPES buffered physiological salt solution containing NaCl, KCl, 
MgSO4, KH2PO4, CaCl2, glucose, HEPES and media including: DMEM and Nutrient Mixture F-12 Ham were all 
obtained from Sigma Aldrich (St. Louis, Missouri, United States). Drugs injected into the murine models; 
Methandienone and 20HE, were obtained from Toronto Research Chemicals (North York, Ontario, Canada) 
and Sigma Aldrich respectively.  
The two supplements chosen for the human in-vivo study; Desire-X and Z-force were obtained online through 
Amazon.com (USA), from Manson vitamins and Dymatize nutrition respectively.  The sources of the remaining 
14 supplements analysed are summarised in (Table-3). Other reagents used in the in-vivo studies included: β-
glucuronidase from E. coli; Roche Diagnostics (Basel, Switzerland), Diethyl ether; Merck (Kenilworth, New 
Jersey, United States), MSTFA; Carl Bucherer (Lucerne,Switzerland), 2-propanthiol; Merck, Iodoacetamide; 
Biorad (Hercules, California, United States), ammonium formate; Agilent Technologies (Santa Clara, California, 
United States) and LC Grade acetonitrile & 1,4-dithiothreitol (DTT) were both obtained from Merck. 
Reagents for the extraction and processing of DNA, RNA and protein were obtained from various vendors; 
Ethanol; Ciba-Chem (Basel, Switzerland), Phosphate Buffered Saline (PBS); Gibco (Waltham, Massachusetts, 
United States), DEPC water &TRIzol reagent; Ambion (Austin, Texas, United States) and Formic acid; Merck. 
Kits used were GeneChip WT PLUS Reagent Kit & High-Capacity cDNA Reverse Transcription kit; Applied 
Biosystems (Foster City, California, United States), Pierce BCA protein assay kit; Thermo Scientific (Waltham, 
Massachusetts, United States) and Trypsin/Lys-C Mix, Mass Spec Grade V5072; Promega (Madison, Wisconsin, 
United States). β-actin Primer Assays, first strand cDNA synthesis kit, Pathway specific: Human/Mouse drug 
Metabolism: Phase I Enzymes, Human Drug Metabolism PCR Array and ABI SYBR Green master mix were all 
obtained from Qiagen (Hilden, Germany). Finally, ALDH Activity Assay Kit was obtained from BioVision 
(Milpitas, California, USA).  
Materials used for the validation study included cryopreserved Human Coronary Artery Endothelial Cells 
(HCAECs), Endothelial Cell Growth Media and supplement pack and were all obtained from Promocell 
(Heidelberg, Germany) while attachment factor was obtained from Gibco.  SeeBlue plus2 protein standard 
marker was obtained from Invitrogen, mouse monoclonal anti-eNOS antibody (M221) purchased from Abcam 









Turkesterone Thailand S5 supplement labs 14 days None 
Ecdybolin Russia eBay (Truly huge supplements) 7 days None 
Suma root USA eBay (Swanson health products) 6 days None 
Desire-X USA Amazon  (Manson vitamins) 12 days None 
Immunectar USA eBay (Natural organics laboratories, inc) 8 days None 
Natural Sterol 
extreme 




China Made in China (Shaanxi Sinuote Biotech Co. 
Ltd) 
7 days None 
ZMA PM USA eBay (Kaizen nutrition) 14 days None 
Beta-X USA Bonanza (Mass nutrition) 10 days None 
Norateen II UK eBay (LA muscle) 7 days None 
Z-Force USA Amazon (Dymatize nutrition) 14 days None 




Canada Nutrichem 20 days Declaration 
form 
Power meal USA eBay (Young living essential oils, LC) 14 days None 
Animal Stack 
(USA) 




UK eBay (Maxi nutrition (GSK healthcare) 15 days None 
 
(Table-3) Origin, seller sources and shipping details of the 16 supplements analysed for the human in-vivo 
study to investigate their ecdysteroids content. Out of 149 supplements and preparations claiming the 
content of ecdysteroids reported by Lafont et. al. (55) only 16 were obtainable due to different reasons 





Cells, media and reagents used for the measurement of mitochondrial membrane potential were obtained as 
follows; Human White Preadipocytes (HWP) from the subcutaneous adipose tissue depots of normal weight 
subjects Cat no: C-12730, Lot no: 395Z024 were obtained from Promocell and HSMM-Muscle Myoblasts, basal 
media, SkGM™ SingleQuots supplement pack were all obtained from Lonza (Basel, Switzerland). Tetramethyl 
rhodamine methyl ester (TMRE) for the staining of the mitochondria was obtained from Invitrogen (Carlsbad, 
California, United States).  
A wide range of instruments were used in these studies. The instruments used for the extractions, quality 
assessment and downstream analyses of DNA, RNA and protein included GLS Aqua 12 Plus water bath & QBD2 
Heat block; Grant (Cambrigeshire,UK),  Dounce all glass tissue grinder; Kimble Chase (Vineland, New Jersey, 
USA) Genius 3 Vortex; IKA (Staufen, Germany), 5424 R Centrifuge; Eppendorf (Hamburg, Germany), SL16R 
Centrifuge and  SeriesII water Jacket Co2 incubator both from Thermo Scientific (Waltham, Massachusetts, 
United States) in addition to the quality assessment instrument; NanoDrop while the Bioanalyzer was obtained 
from Agilent .The ViiA7; Applied Biosystems (Foster City, California, United States) and the Infinite 200 PRO 
plate reader; Tecan (Männedorf, Switzerland). For the transcriptome analysis the GeneTitan instrument was 
utilised; Affymetrix (Santa Clara, California, United States). 
For the detection of urinary metabolites and the proteomics analysis these instruments were used: UHPLC, 
QExactive Orbitrap-based mass spectrometer and ELITE Orbitrap LC/MSMS from Thermo Scientific and Zorbax 
Eclipse Plus C18 column, GC 7890 system, 7000C triple quadrupole mass spectrometer from Agilent 
technologies in addition to LabRoller Lab Rotator mixer from Thomas Scientific (Swedesboro, New Jersey, 
United States). 
For the human anthropometric measurements and body composition electrical bioimpedance MC 980MA 
TANITA (Tokyo, Japan) was used. Quark CPET Cosmed (Rome, Italy) was used for the assessment on aerobic 
fitness and physiological responses to exercise. Haematology tests and clinical chemistry assays were 
conducted on the XT4000i instrument from Sysmex (Kobe, Japan) and the Roche Cobas integra 400 plus; Roche 
(Basel, Switzerland) respectively. Finally, Leica confocal microscopy (Wetzlar, Germany) was utilised for the 
mitochondrial membrane potential measurements. 
Software used for the statistical analyses were Microsoft Excel; Microsoft (Redmond, Washington, United 
States), SA Biosciences online data analysis / Gene Globe Data Analysis Centre; QIAGEN (Hilden, Germany), 
Transcriptome Analysis Console TAC Version 4.0; Affymetrix (Santa Clara, California, United States), Raw Meat 
proteomics data analysis software, Proteome Discoverer PD Thermo scientific. Web-based data analysis tools 
were also used for functional enrichment analysis on gene and protein lists exported from the transcriptome 
and proteome analyses included STRING version 11.0 (91), g:Profiler  (92)and freely available to download 
software FUNRICH VERSION3.1.3. 
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Murine Studies. All the mouse in-vivo experiments were conducted at KMT Hepatech lnc. (Edmonton, Canada) 
and approved by the Laboratory Animal Ethics Committee. It is noteworthy that in 2017 KMT Hepatech 
became part of PhoenixBio group. 
Human Studies.  The study was approved by Anti-doping lab institutional review board (Ref. F2018000296) 
and conducted in the licensed clinic of ADLQ, which was fully equipped to facilitate all the later described 
protocols with minimal risk to the participants. 
 
2.2Methods 
Metabolites and excretion profiles studies have mainly been conducted in-vitro using human hepatocytes. 
Often such studies don’t provide similar results to those conducted in-vivo in clinical studies. It is known that 
clinical in-vivo investigations are governed by strict ethical guidelines hence, to investigate physiological 
effects of 20HE or any other substance, a suitable in-vitro and/or in-vivo models were sought. The need for an 
alternate model was addressed by Lootens et. al. (76) where their study examined the use of uPA+/+ SCID 
mouse model for such investigations. The initial aim was to confirm the results obtained by Lootens et.al (76) 
on the metabolism of the gold standard doping agent, Methandienone. This study aimed to validate the use 
of the model at ADLQ facilities, with the in-vivo portion of the experiment conducted at KMT facilities in 
Edmonton, Canada. After confirming the detection of the human hepatic metabolites of this doping agent, the 
second part aimed to investigate the metabolism of 20HE using the same uPA+/+SCID mouse model after its 
suitability was confirmed. 20HE excretion was investigated using urine samples obtained from the SCID mice 
and in a single human volunteer administered with 20HE in its pure form and as a constituent in  a supplement. 
These studies were conducted using one common route of drug excretion which is the urinary route.  
Although human in-vivo models offer the best results they are very challenging due to ethical restrictions. In 
this study specifically, 20HE has been reported to have, in addition to the anabolic activity, side effects that 
can be considered threat to health, including non-specific organ hypertrophy (54). This created an ethical issue 
that compromised any human in-vivo study where 20HE is administered in its pure form. Though the uPA+/+ 
SCID mouse model explored in the first aim was one way of addressing this issue, it came with many limitations 
since it was only the human liver within the model that can be studied. This excluded the ability to look at any 
systemic effects due to the compromised nature of the model. In the following study, the ethical issue of in-
vivo administration of a drug was addressed in a different manner than in the first study, which utilised the  
mouse model with humanised liver, by the investigating the effects of 20HE in-vivo in humans by administering 
a specific concentration of 20HE as a component of a supplement that was readily available in the market. 
Sixteen supplements were obtained from different sources claiming ecdysteroid content and then were 
analysed to quantify 20HE concentration (Table-3). Two supplements were chosen for the human study based 
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on their ecdysteroid content concentrations. The first supplement; Desire-X consisted of 20HE concentration 
that was lower than the reported anabolic concentration. The second supplement (Z-Force) had undetectable 
amounts of 20HE and was used as a control. Supplements intervention was given to healthy recreational 
athletes for two months and before-and-after parameters were measured, recorded and analysed.  
Literature showed the anabolic effects of 20HE in muscles in rats and mice (66,73) and anecdotal reports 
indicated the reduction of fat mass in response to 20HE. To further investigate this the effects of 20HE on 
mitochondria in-vitro in Human Skeletal Muscle Myoblasts (HSMM) and Preadipocytes was investigated. In 
mitochondrial respiration, energy stored in micronutrients is converted to ATP which is the cellular energy 
donor. This is done by the oxidation of micronutrients coupled with ATP synthesis (94). In this study confocal 
microscopy was utilised to measure the coupling of mitochondria after treatment with different 
concentrations of 20HE. 
Finally, molecular mechanisms relating to metabolism and physiological effects of 20HE were investigated. 
This was done at the RNA and protein level extracted from the humanised liver SCID mice model treated with 
20HE. Whole transcriptome and proteome approaches were used, and data analysis was conducted in-house 
and taken further with collaboration with Qatar Computational Research Institute QCRI. 
2.2.1 Investigation of 20HE metabolism 
2.2.1.1 Metabolism of Methandienone  
Animal study 
All in-vivo mouse experiments and procedures were approved by the Laboratory Animal Ethics Committee and 
were carried out at KMT Hepatech lnc. uPA+/+ SCID mice were transplanted with primary human hepatocytes 
(chimeric mice). Non-chimeric uPA+/+ SCID mice without transplanted human hepatocytes were used as 
controls. Prior to administration of the drug, human albumin concentrations were determined in the plasma 














(Figure-11) Methandienone/placebo-treated uPA+/+ SCID mice experimental design and sample collection.  
Mice with humanised liver (chimeric) were administered with drug (n=3) or placebo (n=3) in a single dose (a) 
similar experiment were conducted as a control on non-chimeric mice administered with drug (n=2) or placebo 
(n=2). Another experiment design was conducted with multiple dosing (b) where chimeric (n=6) and non-
chimeric (n=4) mice were administered with either the drug (n=3) and (n=2) respectively or placebo (n=3) and 
(n=2) respectively. Urine samples were collected every 24 hours and on day4 animals were sacrificed. Urine 













 The chimeric mice which were successfully transplanted with human liver (n=12) were divided to two groups. 
The first group (n=6) was administered with (100µl of 400mg/L) of methandienone in a single dose (n=3) or 
multiple doses (n=3). The second control group (n=6) was administered with placebo; 5% ethanol/PBS in single 
dose (n=3) or multiple doses (n=3). Drug and placebo administrations were done by oral gavage. Similarly, non-
chimeric mice were divided in to two groups. The first group (n=4) was treated with methandienone in single 
dose (n=2) or multiple doses (n=2) while the second control group (n=4) was administered with placebo; 
5%ethanol/PBS in a single dose (n=2) or multiple doses (n=2).  Methandienone was administered by oral 
gavage on day 0 for the single dose group (Figure-11a), and on days 0, 1 and 2 of the experiment for the 
multiple doses group (Figure-11b).  
 
Urine samples from all groups were collected, noninvasively over a 24h period, on days 0 prior to the drug 
administration and on days 1, 2, 3 and 4 after the drug administration. All samples were then stored at -20°C. 
A total of 20 mice were used in this study (Table-4). All animals were sacrificed by Schedule 1 protocol at the 
end of the experiment. Blood plasma was obtained by cardiac puncture with anticoagulant following which 
the livers were harvested. Livers were flash frozen and samples (urine, plasma and liver tissue) were stored at 
-80°C until transported to ADLQ on dry ice for analysis.  
 
Urinary metabolites analysis 
All urine samples collected from the uPA+/+ SCID mice were analysed by Ultra-Performance Liquid 
Chromatography–High-Resolution Mass Spectrometry (UHPLC/HRMS) and Gas chromatography mass 
spectrometry (GCMS) for the detection of the parent drug and its major metabolites. Additionally, a blank 
human urine sample fortified with reference standards of the previously reported metabolites was analysed 
to confirm the presence of the detected metabolites.  
 
Hydrolysis 
In a glass tube 400µL of urine was mixed with 75µL of ß-Glucuronidase enzyme 20KU/141mL, 500µL Phosphate 
buffer (pH7) and 25µL on internal standard consisting of a mixture of 6 steroids. The tube was then sealed and 
vortexed for few seconds and incubated in the oven at 55⁰C for 1hour after which it was cooled for 5-10 
minutes. Glucuronidase enzyme cleaves the sugar group (COOH) in all the OH groups which only works at pH7 






After hydrolysis, one spoon (≈ 0.5g) of NaHCO₃ and 5mL Diethyl ether were added. The tube was again sealed 
and vortexed for few seconds. Hydolysis caused ionization and the addition of NaHCO₃ increased the pH to 10 
deionizing compounds of interest. The tube was then placed on a LabRoller rotator to mix at a moderate speed 
for 20 minutes to separate the organic phase from the aqueous phase. After the incubation the tube was 
centrifuged at 3000RPM for 12 minutes and placed in a  -80⁰C freezer in a rack filled with ethanol to speed up 
the freezing process. Compounds of interest then separate into the organic phase in ether -which doesn’t 
freeze at -80⁰C- from the frozen solid aqueous phase. The organic phase was then collected in a new falcon 
glass tube and the sample was evaporated in a heat block at 55⁰C with nitrogen flow until fully dry.  After this 
LC and GC analyses protocol differ where for LC analysis, 100 µL reconstitution buffer (80%A|20%B) was added 
and sample was transferred to injection Vials. And for GC analysis derivatisation process is done to the dried 
sample where 50µl of derivatisation reagent consisting of 100mlMSTFA + 400mg NH₄I+300µL 2-Propanthiol 
was added to the tube and incubated on a heat block at 55⁰c for 1 hour. The functions of the constituents of 
the derivatisation mixture were; NH₄I for the removal of H+ from the compounds of interest, MSTFA used for 
Silylation process that involve replacing H+ in compounds of interest and finally 2-Propoanthiol was used to 
react with the excess NH₄I. The samples were then transferred to injection vial of GCMS instrument Agilent 
GC 7890 coupled with an Agilent 7000C QQQ MS, equipped with an Agilent 7693 auto-sampler.  
 
UHPLC/HRMS conditions were as follows; the Dionex UHPLC system was used for the chromatographic 
separation according to established method in the anti-doping lab. This system consists of a vacuum degasser, 
a high-pressure binary pump, an autosampler with a cooled sample tray and a column oven. Chromatographic 
separation was performed at 40°C using a Zorbax Eclipse Plus C18 column (100 x 2.1mm i.d., 1.8 mm particle 
size). The mobile phase consisted of 5mM ammonium formate in 0.02% formic acid (solvent A) and a mixture 
of acetonitrile/water (90:10 v/v) containing 5mM ammonium formate and 0.02% formic acid (solvent B). A 
gradient elution program was employed at a constant flow rate of 0.2 mL min-1. The analysis run time was 20 
minutes and the injection volume was 5µL.The high-resolution mass spectrometry was performed using a 
QExactive Orbitrap-based mass spectrometer. GC/MSMS analysis was performed using Agilent GC 7890 system 
coupled with Agilent 7000C triple quadrupole mass spectrometer equipped with a 7693 autosampler and 
chromatographic separation was achieved using a SGE BPX5 column. The MS system was a QQQ with Electron 
Ionization at 70eV and multiple reaction monitoring (MRM) acquisition for the detection of methandienone 





















(Table-4) Animals allocated to single and multiple doses of Methandienone. Eight chimeric uPA+/+ SCID mice 
were treated with either Methandienone or placebo (placebo) in single dose (left) or in multiple doses (right). 




















Animal ID # 
 
Treatment 









































To extract the RNA, liver tissue harvested from the experimental animals was placed on ice and kept frozen by 
frequent exposure to liquid nitrogen while grinding the tissue to fine powder using pre-chilled mortar and 
pestle.  TRIzol reagent was added to disrupt the cells for complete cell lysis. RNA was then precipitated with 
isopropanol; the pellets were washed with 70% ethanol and after airdrying, the pellet was resuspended in 
Nanopure DEPC water and stored at -80oC until further analysis.  RNA quality was checked using the NanoDrop 
and the Bioanalyzer where RNA Integrity Number (RIN) of 5.5 was considered acceptable for expression 
studies.  cDNA was synthesised using Qiagen first strand cDNA synthesis kit. To eliminate genomic DNA 
contamination, RNA samples were incubated with GE buffer for 5 minutes at 42°C, samples were then placed 
immediately on ice for at least 1 min. Reverse transcription master mix was then prepared for all samples 
which consisted of the buffer, control and reverse transcriptase enzyme. The mix was then added to all RNA 
samples and incubated at 42°C for exactly 15min. The reaction was immediately stopped by incubation at 95°C 
for 5 min. RNase free water was then added to each sample. For pathway specific microarray analysis cDNA 
was added to SYBR green mixture and loaded into the 96 well plate array. The array was then sealed and 
centrifuged for 1 minute at 1000 g at room temperature to collect the contents to the bottom. The array was 
then loaded into the ViiA7 real time PCR instrument with these cycling conditions: activation by heating at 
95°C for 10 minutes, annealing and elongation at 95°C for 15 seconds and 65 °C for1 minutes respectively for 
40 cycles and finally fluorescence data were collected. This protocol was applied for the human and mouse 
Drug Metabolism: Phase I Enzymes PCR Arrays to assess the expression of 84 key Phase 1 drug metabolism 
genes by real time PCR (appendix-2). Endogenous reference RNA controls were used to normalise the amount 











Aldehyde dehydrogenase activity in blood 
The aldehyde dehydrogenase activity in plasma was investigated in response to methandienone using the 
ALDH Activity Assay Kit (BioVision’s PicoProbe). The assay was conducted on Infinite 200 PRO Microplate 
Reader from Tecan according to the manufacturer’s protocol in kinetic mode. The kinetic cycle was of 2-minute 
interval for 1 hour. Fluorescence intensity was measured from the bottom of the plate at Ex/Em 535/587 nm. 
The reading was recorded after 10 flashes with manual gain of 100. 
The ALDH activity=B (ΔT x V) x sample dilution factor = pmol/min/mL = µU/ml. 




2.2.1.2 Metabolism of 20HE 
Animal study 
uPA+/+ SCID mice were transplanted with primary human hepatocytes and human albumin concentration was 
determined prior to drug administration to confirm the engraftment of human hepatocytes. Non-chimeric 
mice served as control animals. Chimeric mice (n=8) were administered with multiple doses of 20HE (n=4) or 
5% ethanol/PBS placebo (n=4). Similarly, non-chimeric mice (n=2) were also administered with 20HE (n=1) or 
5% ethanol/PBS placebo (n=1). 20HE was administered by oral gavage at a concentration of 200µg/gavage 
(100µl of 2.0mg/ml) on day 0, 1 and 2 of the experiment.  Metabolic cages were used to collect urine samples 
noninvasively from all animals on days 0,1,2,3 and 4 of the experiment and stored at -20°C. All animals were 
sacrificed by Schedule 1 protocol at the end of the experiment (Figure-12). Blood was obtained by cardiac 
puncture with anticoagulant using EDTA tubes. Livers were harvested and flash frozen. Samples (urine, plasma, 














(Figure-12) 20HE\placebo treated uPA +/+ SCID mice experimental design and sample collection.  Male 
chimeric (n=8), non-chimeric (n=2) uPA+/+ SCID administered with 200µg/gavage 20HE or placebo by oral 
gavage, in multiple doses. 24h urine collections were made prior to and daily following drug administration 
















Urinary metabolites analysis 
Gas Chromatography analysis started with addition of 1mL of phosphate buffer at pH7 (0.8M K2HPO4 and 0.4M 
KH2PO4), 50µL of β-glucuronidase from E. coli and 50µL of a methanolic solution of internal standards mixture 
to 0.5 mL of urine sample.  The mixture was then hydrolysed by incubation at 50°C for 1.5 hours. After 
hydrolysis, the pH was adjusted to 9–10 with sodium hydrogen carbonate and potassium carbonate (2:1) 
(w/w). A liquid–liquid extraction against 5mL of diethyl ether was performed. After centrifugation, the organic 
layer was separated from the aqueous phase by freezing and evaporation under nitrogen at 50°C. Prior to 
GC/MSMS analysis, a derivatisation step was performed to the dry residue by adding 25µL of 




RNA extraction was carried out as detailed previously by grinding the frozen tissue in liquid nitrogen. TRIzol 
was added to disrupt the cells and RNA was precipitated using alcohol precipitation method. The quality was 
checked using a Bioanalyzer and NanoDrop. cDNA was synthesised and used for pathway-specific human drug 
metabolism PCR arrays (Qiagen) to assess the expression of 84 key drug metabolism genes by real time PCR 














2.2.1.3 Human Excretion study  
To conduct excretion studies, the quality and quantification of 20HE sources must be analysed. So, 16 
supplements that claimed having ecdysteroid as a component were analysed by GCMS. Based on the results 




The extraction step started with dissolving each capsule by shaking in 5mL of carbonate buffer at pH 10-11 for 
30 minutes. Then, 5mL diethyl ether was added and samples were incubated for another 30 minutes with 
shaking. The mixture was then centrifuged at 3500 RPM for 10 minutes to separate the organic layer, which 
was evaporated under nitrogen flow. The pellet was reconstituted in 200µl of mobile phase (100% water 
containing 5mM ammonium formate in 0.02% formic acid) and analysed using GCMS to detect 20HE 
quantitatively. Interestingly supplement quantification showed that Turkesterone supplement was 
mislabelled and contained 2.3mg of 20HE.  
 
Excretion study 
The excretion study started with the recruitment of one healthy 43 years old volunteer weighing 90Kgs who 
declared not to have used any nutritional supplements or medications during the last 3 months. A blank urine 
was collected and a single 2-tablet dose of Turkesterone supplement (recommended dose by the 
manufacturer) was administered. Urine samples were collected before taking the supplement on day one and 
continued after taking the supplements for a total of 4 days. After a 45-days washout period, the same 
volunteer was again recruited and administered with a single dose Desire-X supplement which after 
quantification yielded a lower concentration of 20HE compared to Turkesterone supplement. The dose 
consisted of 2 tablets taken on day one and urine samples were also collected for 6 days thereafter. All the 
urine samples were stored frozen at -20°C until analysis by GCMS.      
This concluded the methods relating to the investigation of 20HE metabolism. The 16 supplements that were 
analysed by GCMS revealed ranging amounts of 20HE concentrations within each supplement and this 
intrigued further exploring of the possible physiological effects in humans in-vitro and in-vivo. As higher 
concentrations of 20HE were reported to be anabolic in mammals the following investigation aimed to 
examine the possible physiological effects of 20HE at lower concentrations.  
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2.2.2 Physiological effects of Ecdysteroids 
2.2.2.1 Human in-vivo study 
 
A cohort of non-diabetic normotensive recreational athletes with no history of supplement intake for the 
previous 3 months was recruited by word of mouth (Table-5). The criteria for inclusion or exclusion from the 
study is summarised in (Appendix-3). Volunteers who passed the inclusion criteria were divided to two groups; 
group 1 received the 20HE containing supplement Desire-X (n=6) and group 2 received Z-force as a placebo 
supplement (n=6). During the first visit all participants signed an informed consent form (appendix-4) and 
completed a questionnaire detailing their dietary intake and training schedule and co-morbidities on the day 
of study. After that baseline measurements were recorded including anthropometric measurements; body 
mass index – body weight (kg) in light clothing and height (m) were recorded. Body composition analysis was 
conducted using bioimpedance Tanita MC980MA. Systolic (SBP) and diastolic blood pressure (DBP) were 
recorded using automatic digital blood pressure monitor and then mean arterial BP MAP) was calculated. 
Multiple urine samples were collected from participants taking Desire-X (20HE) before and during the 
intervention to ensure compliance by taking the supplement. All groups were residing in Doha, Qatar for the 























Phase  Time of visit / duration Procedure  
 
1: Screening  
and intervention 
 
Morning/ 4-6 hours 
 
Screening in a fasting state: Questionnaire, Body 
Composition, anthropometric measurements, BP, 
CPET aerobic fitness,  Blood sampling and urine 
collection. 
Intervention: Volunteers were asked to start the use 





Morning/ 4-6 hours 
 
Post intervention screening: Body Composition, 
anthropometric measurements, BP, CPET aerobic 





Blood was tested using Sysmex (haematology tests) 
and Cobas integra 4000 (chemistry tests). Urines were 
analysed by GCMSMS for the detection of metabolites. 
Data were analysed using SPSS. 
 
(Table-5) Human in-vivo study Scheme consisting of three phases. Phase1: Screening and baseline 
measurements recording then the start if the intervention, Phase 2: Post intervention measurements 

















To investigate the effects on aerobic fitness, Bruce protocol was used before and after supplement 
intervention with or without 20HE using CPET (Cardio pulmonary Exercise Testing). The speed and angle/grade 
of the treadmill was set to increase at 3-minute interval beginning at 10% grade and 2 .7 Km/h for 3-minutes 
and gradual increase up to 22% grade and 9.6 Km/h (Table-6) where VO2 association with the heart rate 
induced and then the VO2max is automatically calculated. 
 
 
Total blood extraction was 12mL at one visit divided into the following tubes with and without anticoagulant 
(3mL each), NF (sodium fluoride) 1mL tube and PAX gene Blood RNA tube. Blood Glucose, Total Cholesterol, 
LDL-Cholesterol, HDL-Cholesterol levels and Triglycerides levels were measured using Cobas integra 400 plus 
and Sysmex was used for haematology tests. Collected urine samples from the 20HE supplement group were 
analysed using GCMSMS. Sample preparation, hydrolysis and derivatisation was done according to the 
protocols detailed in section 2.2.1. Finally, advice on a balanced healthy diet was provided to all volunteers   
both in a face –to –face interview and in the form of printed material. All volunteers were asked to keep a 
food diary for 3 days; two workdays and one day in a weekend for the assessment of quality and quantity of 
























Stage Minutes % grade km/h METS 
1 3 10 2.7 5 
2 3 12 4.0 7 
3 3 14 5.4 10 
4 3 16 6.7 13 
5 3 18 8.0 15 
6 3 20 8.8 18 
7 3 22 9.6 20 
 
(Table-6). Bruce protocol conducted using CPET for the estimation of cardiorespiratory fitness (aerobic 
fitness). Each stage is held for 3 minutes and grade% which refer to the treadmill angle is increased by 2% 





















2.2.2.2 Human in-vitro studies  
Preadipocytes Mitochondrial membrane potential 
Primary human white preadipocytes from the abdominal subcutaneous and visceral adipose tissue depots 
were obtained from non-diabetic female and male subjects respectively and their characteristics are detailed 
in (Table-7).  Cryopreserved cell pellets were resurrected in the recommended growth media and grown as 
per manufacturer’s recommendations. The resurrection was successful, and the cells expanded over two 
generations (i.e. passaged twice; P2). The P2 cells were counted and 30,000 cells in 1mL of media was used 
for the following studies. Cells were cultured until approximately 80% confluence on polystyrene tissue culture 
plates.  
To measure mitochondrial membrane potential (∆Ψm MMP) initially two thousand cells from each 
preadipocyte depots were seeded on two glass coverslips each and were allowed to adhere onto the matrix 
overnight, at 37⁰C and 5% CO2. One coverslip per cell type was treated with 10µM of 20HE and one acted as 
control (without treatment), both were incubated overnight at 37⁰C with 5% CO2. Dose response studies were 
then conducted where four coverslips comprised one experiment consisting of 0 ,1, 5 & 10 µM 20HE 
treatments. After 24 hours of treatment cells were washed with HEPES buffered physiological salt solution 
containing 156mM NaCl, 3mM KCl, 2mM MgSO4, 1.25mM KH2PO4, 2mM CaCl2, 10mM glucose and 10mM 
HEPES, and pH was adjusted to 7.4 with NaOH. After three washes the cells were incubated in 30 nM 
tetramethyl rhodamine methyl ester (TMRE) for 30 minutes to stain the mitochondria. TMRE is a lipophilic 
cationic dye that equilibrates between compartments in response to potential differences. TMRE was used at 
very low concentrations (30 nM), when the signal is proportional to dye concentration, which in turn depends 
on the potential differences between compartments, so that comparative estimates of ∆Ψ may be obtained 
from confocal images. After the incubation, TMRE fluorescence was excited using a single wavelength of 543 
nm HeNe laser line and measured at >590 nm using Leica confocal microscope. A decrease in TMRE signal 
indicates mitochondrial membrane depolarisation. Quantitative measurements of TMRE intensity per field 
was made using the inbuilt software. Further these parameters were measured following uncoupling with 









RNA and cellular protein extraction 
Cells of the same batch and passage number were used in these experiments so that mRNA and protein 
expression were truly representative of those that had mitochondrial function measured. The cells were 
grown in 6-well plates to confluence before being treated with 20HE overnight. The control cells were treated 
with media only, minus the 20HE. The media was decanted, and the plates kept on ice throughout. The cells 
were washed once with ice cold PBS and any excess removed. RNA was extracted with TRIzol from these cells 
as previously described.  
 
Extraction of cellular protein using RIPA buffer  
The cellular protein was extracted by adding 500 µl of RIPA Lysis Buffer with inhibitors to each well and shaken 
from side to side to distribute evenly. The cells were scraped off the plate and the lysate transferred to a 15 
mL conical tube. The lysate was vortexed vigorously for 5 minutes for three times and then incubated on ice 
for 15 minutes before being centrifuged at 13,000g for 5 minutes at 4°C. The supernatant was collected into 
fresh 1.5mL Eppendorf tubes, without disturbing the pellet. The protein concentration was estimated on the 






















Product Name HWP HWP 
Order Number  C-12732 / C-12733 C-12730 / C-12731 
Lot Number  410Z041.2 419Z023 
Donor Age / Sex / Race  56 / Male / Caucasian 45 / Female / Caucasian 
Tissue / Localisation  visceral adipose 
tissue / omentum 
subcutaneous adipose 
tissue / abdomen 
Number of Viable Cells  600.000 600.000 
Stage of culture shipped in passage 2 
(3rd culture) 
shipped in passage 2 (3rd culture) 
 
(Table-7) Characteristics of primary visceral and subcutaneous human white preadipocytes (HWP). Details 
of the cells used in the first set of experiments conducted on the confocal microscopy for the investigation of 


















Test method for combined DNA, RNA and Protein extraction from treated cells 
In addition to the conventional method used for RNA and protein extraction from cells, a combined procedure 
described here was attempted. 500µl of Trizol reagent was added to each well containing cells and incubated 
on ice for 5minutes to homogenise and lyse the cells. The cells were then scraped and transferred into 
microtubes. One hundred microlitres of chloroform was added and the tube was vortexed vigorously for 15 
seconds and then incubated at room temperature for 3 minutes. The tubes were spun at 12,000 RPM for 15 
minutes at 4°C. This caused the separation of the aqueous and organic layers. The clear upper aqueous layer 
(approximately 500 µl) contained the RNA and to it an equal volume of isopropanol was added and left at -
20°C overnight. The precipitate was centrifuged for 15 minutes at 14,000 RPM and 4⁰C. The isopropanol was 
aspirated very carefully, and the pellet washed twice with 0.8mL of 75% ethanol by resuspending and 
centrifugation 5 minutes at 14,000 RPM and 4°C. After the last wash, the ethanol was removed carefully, and 
the pellet was air-dried on ice with cling film on top and the 1.5 mL tube lid open for 10 minutes, small holes 
were punched in cling film to allow air exchange. The RNA was resuspended with 45µl RNase free water and 
incubated at room temperature for 10 minutes, vortexed and incubated on ice for 10 minutes before 
measuring concentrations using NanoDrop. The RNA was stored in -80⁰C. 
 
To the lower organic layer after separation containing DNA and protein 0.3 mL of 100% ethanol was added. 
Samples were mixed by repeated inversion and incubated at room temperature for 2-3 minutes. The DNA was 
pelleted by centrifugation at 2,000g for 5 minutes at 4°C and the phenol-ethanol supernatant transferred to a 
new tube. The supernatant was used for protein extraction where 750µl of isopropanol was added to the 
phenol-ethanol supernatant and incubated for 10 minutes and centrifuged for 10 minutes at 12,000RPM at 
4°C to pellet the proteins. The supernatant was aspirated and discarded with a micropipette. The protein pellet 
was resuspended with 1mL of 0.3 M guanidine hydrochloride in 95% ethanol to precipitate the proteins by 
incubation for 20 minutes. The suspension was centrifuged for 5 minutes at 10,000 RPM at 4°C and 
supernatant discarded with a micropipette. This step was repeated twice. 2mL of 100% ethanol was added 
and mixed by vortexing briefly. The tubes were incubated for 20 minutes before being centrifuged for 5 
minutes at 10,000RPM at 4°C and the supernatant aspirated and discarded with a micropipette. The protein 
pellet was air dried for 5–10 minutes and the pellet resuspended in 200 µL of 1% SDS by pipetting up and 
down. To ensure complete resuspension of the pellet it was incubated at 50°C heat block. The quality was 






The pellet containing the DNA after organic layer centrifugation was resuspended in 500µl of 0.1M sodium 
citrate in 10% ethanol with pH of 8.5 and incubated for 30 minutes, mixing occasionally by gentle inversion. 
The sample was centrifuged then for 5 minutes at 2000 × g at 4°C and the supernatant was aspirated and 
discarded. The pellet was washed again and then resuspended in 750µl of 75% ethanol, before incubation for 
10–20 minutes, mixing occasionally by gentle inversion. The sample was centrifuge for 5 minutes at 2000 × g 
at 4°C and the supernatant was aspirated and discarded as described above. The DNA pellet was air dried for 
5–10 minutes and resuspended in 300µl of 8mM NaOH by pipetting up and down. The sample was centrifuged 
for 10 minutes at 12,000 × g at 4°C to remove insoluble materials and the supernatant transferred to a new 
tube. The pH was adjusted to 7.5 with HEPES buffer and 1 mM EDTA was added. The DNA was stored at -20⁰C. 
 
 
Preparation of cDNA 
The High-Capacity cDNA Reverse Transcription kit was used. RT kit components were thawed on ice. The 
volumes required of each reagent were calculated according to the number of reactions needed. The master 
mix was prepared and kept on ice as described in (Table-8). Ten microlitres of the RT master mix was added 
to each reaction tube, followed by the addition of 10µl of RNA sample. The tubes were sealed and centrifuged 
to eliminate air bubbles. The reaction tubes were kept on ice until loading on the thermal cycler. The thermal 
cycler was programmed as 25˚C for 10 minutes, 37˚C for 120 minutes, 85˚C for 5 minutes and the reaction was 
then held at 4˚C. The reaction volume was set to 20µl, the reaction tubes were loaded, and the run started. 
Upon completion the cDNA was stored in a fridge at 2-6 ˚C for short term storage or in the freezer -15 to -25 






















 Reagent  Volume in µL 
 10X RT Buffer  2.0 
 25X dNTP Mix (100mM)  0.8 
 10X RT Ramdom Primers  2.0 
MultiScribe™  Reverse Transcriptase  1.0 
 Nuclease Free Water  4.2 
 Total per Reaction  10.0 
 
(Table-8) Preparation of Master mix for cDNA synthesis using High-Capacity cDNA Reverse Transcription kit. 






















Myoblasts mitochondrial membrane potential 
Myoblasts seeding density optimisation 
Human skeletal Muscle Myoblasts (HSMM) from a 35-year-old Caucasian female donor with BMI of 31 were 
resurrected and expanded to passage 2 using Basal media with the addition of SkGM SingleQuots supplement 
pack consisting of human Epidermal Growth Factor (hEGF), Fetuib, Bovine Serum Albumin (BSA), 
Dexamethasone, Insulin, and Gentamicin/Amphotericin-B (GA).  
 
Comparison between the use of cover slips and 4-well chamber slides 
Myoblasts were seeded on cover slips and into 4-well chamber slides for comparison. Four seeding densities 
were tested on 4-chamber slide; these were 5000, 10,000, 15,000 & 20,000 cells per chamber. Cells were also 
seeded on coverslips to compare visualisation under confocal microscopy. 
 
Media comparison 
Two T75 flasks were seeded with the same seeding density of myoblasts. One flask was grown in DMEM while 
the other flask was grown in the manufacturer recommended media; SKGM. Growth was monitored daily 




HSMM mitochondrial membrane potential (MMP) measurements 
Measurement of myoblast mitochondrial membrane potential was conducted using 5x103 cells per coverslip. 
Cell were treated with 20HE at ranging concentrations (0 ,1, 5 & 10 µM). After 24 hours of treatment, cells 
were washed with HEPES buffered physiological salt solution three times and then incubated in 30 nM TMRE 
for 30 minutes to stain the mitochondria. After the incubation, TMRE fluorescence was excited and measured 







2.2.2.3 Molecular mechanisms investigation 
Proteome analysis  
Frozen liver tissue from uPA +/+ SCID mice were ground using pestle and mortar in liquid nitrogen and then 
homogenised using Dounce all glass tissue grinder in RIPA buffer to extract proteins. Samples were then 
centrifuged for 20 minutes at 14000RPM and 4°C. The supernatants were collected and stored in three aliquots 
at -80°C until further analysis. Calorimetric detection and quantification of total protein for all samples was 
estimated using Pierce BCA protein assay kit according to the manufacturer’s instructions. Albumin (BSA) 
Standards were diluted and prepared and the microplate protocol was used. Twenty-five microliters of 
standards and samples were loaded on a U-bottom plate and 200µl of the kit working reagent was added to 
each standard and sample. This was then covered and mixed by vortexing for 15 seconds. The plate was then 
incubated at 37°C for 39 minutes before it was cooled to room temperature and finally the absorbance was 
measured at 562nm on Tecan Plate Reader. 
 
Protein gel run and fragmentation 
Following protein concentration estimation, protein samples of chimeric mice were diluted to 0.85mg/mL. 
From each sample 20µL were mixed with 4µL of 6X reducing buffer to prepare for electrophoresis on 15% 
ExcelGel with running conditions of 600V, 50mA and 30W for 45 minutes. The gel was then washed with 40% 
Ethanol, 10%Acetic acid wash solution. Each sample well was then excised to 8 fragments corresponding to 












In-gel protein digestion 
All 8 protein fragments of all 10 samples were placed individually in a 96well plate. In-gel protein digestion 
using Trypsin/Lys-C Mix, Mass Spec Grade V5072 was conducted according to manufacturer’s instructions. Gel 
pieces were washed by incubation in 200µL of 25mM ammonium bicarbonate at room temperature for 15 
minutes followed by removing the supernatant and additional incubation in 200µl of acetonitrile at room 
temperature for 15 minutes. These alternating steps of incubation were repeated three times for a total of 
four washes. Reduction/Alkylation of the gel pieces was done by adding 200µl of 10mM DTT in 25mM 
ammonium bicarbonate and incubation at 65°C for 30 minutes. The supernatant was removed and the above 
washing steps in ammonium bicarbonate and acetonitrile were repeated four times. Then, 200µL of freshly 
prepared 10mM iodoacetamide in 25mM ammonium bicarbonate was added and the plate was incubated in 
the dark for 45 minutes at 37°C. The wash steps were then repeated four times. The gel pieces were then 
digested with minimal volume (20µL) of 20ng/µL Trypsin/Lys-C Mix solution for 10 minutes. The gel pieces 
were then covered in 60µL of 25mM of ammonium bicarbonate and incubated overnight at 37°C. Ten 
microliters of 1% formic acid was added and the supernatants were collected for analysis. Proteome analysis 


















Transcriptome analysis  
RNA and protein extraction from Liver 
Liver tissue from all samples were weighed and divided into two halves for RNA & protein extractions. RNA 
extraction was done as explained in the previous experiment by grinding the frozen tissue in liquid nitrogen. 
TRIzol was added to disrupt the cells and RNA was precipitated using alcohol precipitation method. Quality 
check was performed on the Bioanalyzer and Nanodrop. RNA samples were stored in -80°C until further 
analyses. 
 
RNA sample preparation 
RNA samples from SCID mice liver tissue treated with 20HE and placebo were prepared in triplicates for whole 
Transcriptome expression analysis using GeneChip WT PLUS Reagent Kit according to manufacturer’s 
instructions. The three-day amplification and labelling process began with first and second strand cDNA 
synthesis reactions respectively from 100ng input. This was followed by an overnight in-vitro transcription for 
the synthesis and amplification of cRNA. cRNA is then purified using magnetic beads and quantified using the 
NanoDrop. Fifteen Micrograms of the purified cRNA is then used as input for the synthesis of 2nd cycle ss-cDNA 
(single stranded complimentary DNA) followed by RNA hydrolysis and removal by RNase H enzyme. The ss-
cDNA was then purified and quantified using the NanoDrop and five micrograms were used as input for the 
fragmentation and the terminal labelling reactions. Finally, the labelled fragments of the ss-cDNA were 
hybridised to the array plate according to manufacturer’s instructions for the GeneTitan instrument where the 
staining and the washing processes were automated. 
Data presentation and statistical tests 
Data were analysed using Excel. Data are shown as mean (±SD), or for non-normally distributed data as median 
(interquartile range), in text and in tables. Comparison of treatments was by paired t-tests and the null 







Proteomics data analysis 
 Raw Meat software and Proteome Discoverer PD were used for data analysis. Quantitative analysis method 
was created on Proteome Discoverer (PD)(Figure-13) to create (.msf) file type in which all the fractions per 
sample have been combined into one file. Individual sample (.msf) files were later loaded/opened together in 
the PD for comparison and easer analysis, i.e.  one result page for chimeric-20HE treated group created from 
4 (.msf) files of four samples. Peptide high confidence filtering (Xcorr cross correlation score) of 1.8, 2.4 and 
2.5 for single, double and triple charge proteins respectively was used while loading the data in order to avoid 
false protein ID identification. The combined data per group, with high confidence peptides, are then exported 
to into a single excel file with a list of all proteins and peptides detected according to the set criteria high 
confidence. In excel, all keratin proteins were excluded which came from skin/hair contamination. Proteins 
that were not detected in all samples within one group were excluded. These will have 0 or no value in the 
coverage column (Column labelled: Score A, Score B, Score C and Score D for all 4 samples per group). All 
proteins that did not have a Score in at least one sample were also excluded. Proteins detected in both 20HE 
treated group and placebo treated group were excluded for the comparative proteomics but used for the 
quantitative proteomics. Each protein detected only in the 20HE treated group is then compared to the 
original (.msf) file of the placebo treated and if it was detected in at least one sample this protein was then 
excluded. This was done also for the proteins detected only in the placebo treated group. Proteins identified 
with only 1 unique peptide were excluded. The minimum of 2 unique peptides was required. Scans from raw 
files were viewed using RawMeat V2 where full scans represent parent peptides and MSMS scans show more 
peaks within the parent compound detected. Trypsin or lysin digestion controls were studied for all samples.  
Protein lists extracted from excel were further analysed using STRING which is an online data analysis tool that 









(Figure-13) Method Created on Proteome Discoverer (PD). PD is a tool on which a workflow is created -like 
the one created in this figure- to process raw data retrieved from the mass spectrometry system and compares 
them to databases of choice to identify the proteins detected. 
 
 
Transcriptome data analysis 
Data analysis was done using freely available software; Transcriptome Analysis Console TAC version 4.0 . 
Expression Analysis Settings used were fold change < -2 or > 2 and  p-value < 0.05 was considered significant 
at gene level analysis. Expression was reported if ≥ 50% samples have detection above background (DABG) 
values below the Threshold.  Exported gene lists were analysed using Microsoft Excel. Functional enrichment 
analysis was also conducted using TAC 4.0. 
Combined functional enrichment analysis was conducted from data generated from the proteome and 
transcriptome analyses using g.profiler (92) which is a web-based analysis tool that shows possible enrichment 
of pathways based on the input gene lists. Protein lists were converted to gene names using UniProtKB.org 
(93) which allowed further analysis was conducted using STRING and FunRich software; a freely available for 
download software that conducts functional enrichment analysis. 
 
Human in-vivo studies data analysis 
data were entered and analysed using SPSS version 25 for Windows. The effect of the supplements was 
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2.2.2.4 Validation  
To validate NOS3 finding, mRNA and protein expression analyses were performed on human coronary artery 
endothelial cells (HCAECs) after treatment with various doses of 20HE. 
 
Cell culture 
HCAECs were thawed in a 37˚C water bath and seeded into a T75 flask pre-treated with attachment factor for 
30minutes at 37˚C in Endothelial cells growth media. Media was changed every 72 hours. At 90% confluence 
cells were then trypsinised after three washes with PBS. After 1-minute incubation in trypsin, media was 
added, and cells were placed in a 15 mL tube and centrifuged at 220g for 5 minutes. Media was discarded, and 
the cell pellet was resuspended in 2mL of media. Cells were then seeded in 6-well plate that was pre-treated 
with attachment factor for 30 minutes at 37˚C. After reaching confluence, cells were starved for 24 hours using 
endothelial cells basal media to reduce effects of supplements on the cell growth. To prepare a 10mM stock 
solution of 20HE, 10mg of 20HE was reconstituted in 2mL of ethanol. Cells in 6-well plate were treated with 
0.1nM, 1nM, 10nM, 100nM, 1µM and ethanol (control).  
 
Protein extraction  
After 24 hours, protein was extracted by removing the media from each well, washing twice with 1mL PBS and 
adding RIPA buffer. After scraping the cells off, the buffer containing the proteins was pipetted into a 15mL 
tube and centrifuged at max speed for 5 minutes. The protein supernatant was collected and used for NOS3 
protein expression investigation by western blot using anti-eNOS antibody (Abcam).   
 
Western blotting 
Protein concentration estimation was conducted using BCA assay according to manufacturer’s 
recommendations detailed in previous section. 20µg of total proteins were added to the reducing agent in LDS 
buffer and incubated at 70 ˚C for 10 minutes. The proteins were then loaded into SDS-PAGE gel, and the gel 
was run for 1 hour at 180V in MOPS running buffer. Proteins were the transferred to nitrocellulose membrane 
at 30V for 2 hours in transfer buffer (100mL methanol,25mL Transfer buffer topped to 500mL with dH2O). 
Membrane was then blocked with 5% milk in TBST for 1 hour. The membrane was then incubated in anti-eNOS 
antibody (1 in 500) overnight. Membrane was then washed 3 times with PBST followed by incubation with 
secondary antibody (1 in 2000) for 1 hour and the membrane was washed 3 times. The membrane was then 
incubated in 2mL chemiluminescence and warped in cling film. In a dark room the membrane was exposed to 
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a film for 15 seconds then the film was washed in a developer then water then exposed to a fixer and finally 
washed with water. 
 
RNA extraction 
RNA was extracted by removing the media from each well, washing each well twice with 1 mL PBS and adding 
350 µL lysis buffer. After scraping the cells on ice, the solution was placed in a 1.2mL tube and an equal volume 
(350µL) of ethanol was added. RNA was extracted using the Qiagen RNeasy kit according to manufacturer’s 
recommendations. The 700µL solution was placed in the spin column provided by the kit and centrifuged at 
13000RPM for 15 seconds. The flow through was discarded and the column was washed with 700µL RWI buffer 
and centrifuged for 15 seconds. The flow through was discarded. 700µL of buffer RPE was then added to the 
column and centrifuged for 15 seconds. Buffer RPE was added again and centrifuged for 2 minutes and the 
flow through was discarded. The column membrane was dried by centrifugation for 1 minute in a new 
collection tube. Finally, the RNA was eluted in 30µL of RNase free water.  
 
qPCR Protocol 
The RNA was used for NOS3 mRNA expression investigation by qPCR using Quantifast SYBR green RT-PCR kit 
where two master mixes were prepared for the extracted RNA to use with eNOS primer and the housekeeping 
gene (HKG) GAPDH for normalisation. To each 10µL of master mix, 2µL of cDNA ,converted from RNA, was 


























Ecdysteroids and specifically 20HE gained the attention of many recreational and elite athletes due to their 
reported anabolic effect (54,66,76). To investigate their effects in humans, and due to in-vivo human studies 
challenges, the previously described uPA+/+ SCID mouse model was used. This was done after confirming the 
model’s ability to generate the human metabolites of Methandienone; gold standard anabolic doping agent 
which was tested after single and multiple dosing experiments. Gene expression studies using drug 
metabolism arrays were carried out using extracted RNA from liver tissue of the experimental mice. Further, 
human excretion study was also conducted in one volunteer in-vivo using a 20HE containing supplement 
presenting an opportunity for extended investigation of 20HE and its effects in humans in-vivo using 20HE 
containing supplement described in the following chapter. 
 
3.1 Metabolism of Methandienone 
3.1.1 Urinary metabolites of Methandienone 
Human hepatic metabolism of Methandienone was assessed using liquid and gas chromatography (LC & GC) 
coupled with mass spectrometry. Liquid chromatography analyses require the compounds of interest to be 
soluble in the mobile phase used in the process. Whereas, gas chromatography analyses require the 
compounds of interest to be derivatized with a mixture of MSTFA/NH4I/2-propanethiol to have better volatility 
and is therefore more suited for smaller compounds. LC, on the other hand, is considered more suitable for 
both small and very large molecules.  
The parent compound Methandienone, the metabolite 17-Epimethandienone and the long-term metabolite 
18-nor-17beta-hydroxymethyl,17alpha-methyl-androst-1,4,13-trien-3-one were analysed Using LCMS (Table-
9). The other metabolites were analysed using GCMS including Epimtendiol, 6bOHmethandienone and 5beta-
methyltestosterone (Table-9). 
LCMS analysis of urine showed the presence of previously reported metabolites of Methandienone, including 
the long-term metabolite, in the drug-treated cohort but not in placebo treated cohort (Figure-14). 
Methandienone was detected 24 hours after drug administration in both single and multiple doses treated 
cohorts. After multiple dosing Methandienone remained detectable up to 48 hours after last administration 
indicating increased detectability in response to multiple dosing which was in line with what’s been reported 







Analyte  Analysis 
type 
Detection 
17-epimethandienone LC   
20B-OH-NorMD GC   
Methandienone LC   
6b-OH-metandienone GC   
18-nor-17beta-hydroxymethyl,17alpha-methyl-
androst-1,4,13-trien-3-one 
    LC x 
5beta-methyltestosterone GC   
18,17b-dihydroxy-17a-methylandrosta-1,4-dien-3-
one 
GC   
16a,17b-dihydroxy-17a-methylandrosta-1,4-dien-3-
one 
GC   
NorEMD(18-normetenol) GC x 
Epimetendiol GC x 
20A-OH-NorMD GC x 
 
(Table-9) Methandienone and the detectability of its urinary metabolites using GCMS and LCMSMS analyses. 
Analyses were conducted using urine samples collected from the uPA +/+ SCID mice administered with 






















(Figure-14) LCMS chromatograms of urine samples before (BLANK URINE) and after single dose administration of methandienone (Left and middle columns 
respectively). The x-axis shows relative intensity of the peak detected plotted against retention time on the y-axis. The right column shows results from the positive 
control. The parent compound Methandienone was detected 24 hours after single administration of the drug and in the positive control. The peak shown in the blank 
urine is considered background because of its low relative intensity indicted by the circled Normalization Level NL=1.19E4 compared to the positive control with 
NL=1.54E5. The long-term metabolite of methandienone; 18-nor-17beta-hydroxymethyl,17alpha-methyl-androst-1,4,13-trien-3-one and 17-epimethandienone were 
detected 24 hours after administration and in the positive control (right column). No peak was detected in the blank urine.  




















        
(Table-10) LCMSMS and GCMS analyses of urinary metabolites of Methandienone from uPA +/+ SCID mice.   
Mice were administered with either a single dose or multiple doses of 20HE and urine samples were analysed 
by LCMS and GCMS.  Table shows that the parent drug and its metabolites were detected 24 hours after the 
first administration of the drug in single and multiple doses. One metabolite: 6β-Hydroxy Methandienone was 
only detected 48hours after first administration of the drug. Multiple doses increased the sensitivity of 















Comparing results from this study to studies from literature where the first study was conducted on healthy 
human volunteer taking 25mg Methandienone and the urinary metabolites were analysed by GCMSMS (66) 
and the second study by Lootens et. al. (76) was conducted using the uPA+/+ SCID mouse model that was used 
in the current study administered with a similar concentration of Methandienone; 40µg per gavage. The 
metabolites that were assayed in this study compared to the other two studies are presented in Table-11. It 
was found that there were three of the metabolites detected in the human urinary study (66) but were not 
detected in studies utilising the uPA +/+ SCID mice which were conducted separately in this project and by 
Lootens et.al (76).  Though it represents 27% of total assayed metabolites this might signify one of the 
limitations of this alternative model. Adding on to the urinary investigation, methandienone metabolism in the 
uPA +/+ SCID mice model was further investigated at the RNA expression level using mouse and human drug 



























Analyte  Parr et. al. 
     (66) 
Lootens et.al. 
      (76) 
This 
study 
EpiMD        
20B-OH-NorMD     
Metandienone     
6b-OH-metandienone     
NorMD   x 
5B-MT  x   
18-OH-MD  Not Assayed   
16A-OH-MD  Not Assayed   
NorEMD(18-normetenol)  x x 
EMD(Epimetendiol)  x x 
20A-OH-NorMD  x x 
 
(Table-11) Comparison of Methandienone metabolites detected by three independent studies. The study 
conducted by Parr et al. (66) was carried out in one human subject given an oral dose (5mg) of the drug, the 
Lootens et al. (76) was a study carried in the same uPA +/+ SCID mouse model as the one used in this study. 









3.1.2 Profiler array analysis 
 
RNA extraction 
Human hepatic metabolism of Methandienone was also investigated at the level of gene expression using 
human phase I drug metabolism enzymes. RNA was extracted from the livers of all the animals, concentrations 
and quality check was conducted on the Nano Drop and Bioanalyzer. Some molecular analyses require specific 
nucleic acid quantity and quality and profiler array analysis requires the sample to be of specific integrity to 
ensure successful and reliable results. The nanodrop is an absorbance-based technique to assess RNA quantity 
is calculated based on absorbance at 260nm and quality is assessed by estimating the presence of protein and 
other contaminants based on the measurement at 280 and 230 nm respectively (86).  The main disadvantage 
in using the Nanodrop is the lack of sensitivity as it does not distinguish between nucleic acids while on the 
other hand the Bioanalyzer is specific to the sample of interest (RNA). The bioanalyzer is an electrophoresis-
based instrument where the nucleic acid is combined with fluorescent dye. The software presents the results 
as electropherograms that include the size and quantity (86) (Figure-15). It provides each RNA sample with an 
integrity number (RIN) based on an algorithm at a scale of 1 to 10 where 10 is the highest RNA integrity (86). 
All the RNA samples used for the profiler array analysis had to have an RNA Integrity Numbers (RIN) of greater 
than 5 (Figure-15). Results indicated that RNA concentrations were too high and thus all samples were diluted, 
and quality check was repeated.  In addition, quality PCR (qPCR) was conducted on all extracted RNA samples 

























NanoDrop Bioanalyzer RTPCR 
RNA Conc. 
(ng/µl)10Xdilution 
RNA Conc. (ng/µl) 
10Xdilution 
RIN β-actin Ct 
S143 SCD 734.9 211 6.8 32.093 
S140 SCD 937.2 129 7.1 20.424 
S035 SCD 419.8 17 7.5 19.859 
S034 SCV 628 20 6.0 20.237 
R909 SCV 1215 70 2.2 20.438 
S036 SCV 618.6 240 6.6 19.225 
R711 SND 797.2 281 6.7 31.688 
R700 SND 1211.4 194 8.1 33.355 
R701 SNV 3141.7 157 2.9 33.406 
R704 SNV 1768.9 181 5.7 33.645 
S053 MCD 491.1 30 2.6 20.847 
S356 MCD 1080.8 183 2.3 22.179 
S049 MCD 883.5 70 2.4 22.426 
S050 MCV 1027.6 247 7.1 20.173 
S355 MCV 946.7 124 7.5 21.001 
S052 MCV 996.9 141 N/A 22.443 
S460 MND 1687.3 179 6.2 31.983 
M-A218 MND 1936.4 103 6.1 33.771 
M-A216 MNV 492.1 99 7.3 19.428 
S458 MNV 926.2 1052 6.8 30.809 
(Table-12) Analyses of RNA extracted from uPA+/+ SCID mouse livers following treatment with 
Methandienone.   RNA samples with a RIN score/value of greater than or equal to 5 were deemed acceptable. 




















(Figure-15) Quality and degradation check of extracted RNA using Agilent Bioanalyzer. Panel (a) shows 
degree of RNA degradation in the gel and this is related to the densitometric analysis and RIN shown in (b). 
These figures are from the manufacturer for reference. (c) represents comparison between my own data 
sample 1 with RIN of 3.50 and Sample 2 with RIN of 8.60. (d) the chromatogram indicating the quality of the 
RNA where in sample 2 (bottom) RIN:8.50 clearly showing two distinct peaks of 18S and 28S whereas sample 










a)                                                                                    b) 
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Mouse Phase I enzymes drug metabolism array 
 
Mouse phase I drug metabolism enzymes profiler arrays were used to examine the response of the humanised 
liver of the chimeric mice to mouse drug metabolism genes and to compare the responses to that of the non-
chimeric mice. Synthesized cDNA from RNA extracted from the SCID mice livers were used for analysis on the 
mouse phase I enzymes drug metabolism array. Fold change differences in gene expression of the chimeric 
mice either treated with methandienone or placebo is presented in a scatter plot (Figure-16). 
 
 
(Figure-16) Scatter plot presenting the expressed genes in the drug treated group after normalisation 
against the control group. Genes that did not show changes in expression after treatment with the drug are 
indicated by the central line and the dotted line represent the fold change cut-off (2.0). Genes that met the 







Significantly differentially expressed genes with p-value≤0.05 were plotted against fold change in a volcano 
plot (Figure-17) and non-hierarchical clustering is illustrated in (Figure-18). It was observed that significantly 
upregulated genes were more than the downregulated genes. These included CYP1A2, CYP27A1 and ALDH3A2 
and genes significantly downregulated were FMO1, ADH5 and CYP2C54.  
 
 
(Figure-17) Volcano plot showing genes that were significantly differentially expressed (p-value ≤0.05) (y-
axis) plotted against fold change (x-axis). Significantly upregulated genes are indicated in yellow and 






(Figure-18) Two-dimensional non-supervised hierarchical clustering of both methandienone and control  





As the mouse phase I drug metabolism enzymes profiler array analysis was conducted on both chimeric/non-
chimeric and drug/placebo treated cohorts, it was observed that the non-chimeric mice mounted little 
response to the drug since the uPA +/+ SCID mice suffer from transgene-induced liver disease that renders the 
mouse liver non-functional.  (Figure-19).  While lower Cycle threshold (Ct) represents over expression, it was 
observed that the Ct distribution for the chimeric mice was higher than that observed in the non-chimeric 
mice after treatment with either placebo or drug. Comparing Chimeric and non chimeric grups both drug 
treated, cycle value range in the non chimeric was mostly less than 25 while the chimeric group had higher Ct 












(Figure-19) Percent Distribution of Values in mouse Phase I drug metabolism array.  Samples from groups of 
mice given either single or multiple doses were combined to increase study power. Lower cycle threshold 




















































































































Human Phase I enzymes drug metabolism array 
 
Human phase I drug metabolism enzymes expression was investigated using profiler arrays (Qiagen). The same 
cDNA that was reverse transcribed from the SCID mice livers was also used to investigate the expression of 
the genes expressing drug metabolising enzymes that are involved in the Human phase 1 drug metabolism 
processes. Prior to the experimental data analyses, RNA and PCR quality assurance was carried out using the 
online SA Biosciences software (Table-13). 
 
In the chimeric animals that had been successfully transplanted with human hepatocytes i.e those measured 
with significantly elevated systemic human albumin, there was a global up-regulation of the Phase 1 
metabolism enzymes in response to methandienone. Data analysis, using ß-actin, B2M and HPRT1 as the 
house-keeping genes for normalisation and excluding samples that did not pass the QC checks, showed the 
mRNA expression of the following genes was significantly induced by the drug, compared to placebo: ALDH7A 
(1.33 fold difference, p< 0.001), ALDH9A1 (2.26 fold difference, p=0.04) and ALDH6A1 (1.88 fold difference, 
p=0.08).Figure-20 shows the fold difference between the two groups and the significance is presented in the 
volcano plot (Figure-21). Cluster gram of both groups is also presented in (Figure-22). Adding on to this finding, 
significance was also observed in the expression of genes from the aldehyde dehydrogenases (ALDH) 
superfamily of enzymes, an ALDH activity assay was conducted using plasma obtained from the SCID mice.  
 
65% percent of the genes in the pathway specific array were induced after drug treatment as opposed to 52% 
following placebo, this was particularly apparent when looking at genes that showed Ct of between 25-30 
(Figure-23A). The non-chimeric mice did not mount a xenobiotic response to the drug, probably because their 











(Table-13) Quality Assurance check of Human Phase I drug metabolism array conducted using SA Biosciences 
online software. Samples in the top table were treated with a single dose of Methandienone and the bottom 
samples were treated with multiple doses. This quality check shows the reproducibility of the array, the 










Chimeric mice single dose 
 
Methandienone treated Placebo treated 
Samples 35 140 143 34 36 909 
PCR array reproducibility Pass Pass Pass Pass Pass Pass 
RT efficiency Pass Inquiry Pass Pass Inquiry Pass 
Genomic DNA 
contamination 
Pass Pass Inquiry Inquiry Inquiry Pass 
Chimeric mice multiple dose 
 
Methandienone treated Placebo treated 
Samples  53 49 356 52 50 355 
PCR array reproducibility Pass Inquiry Pass Inquiry Pass Pass 
RT efficiency Pass Pass Pass Pass Pass Pass 
Genomic             
DNA contamination 








(Figure-20) Scatter plot  presenting normalised expressed genes after methandienone treatment against 
untreated group based on fold change. Central line shows unchanged expression and the upper and lower 
lines represent the fold change cut-off (2.0). Genes that met the fold change threshold are indicated in yellow 















(Figure-21) Volcano plot showing significant changes in gene expression (p-value ≤0.05) plotted against fold 
change. Upregulated genes with positive fold change indicated in yellow dot. Blue dotts present significantly 




(Figure-22) Clustergram of methandienone and control group gene expression. The heat map and 











(Figure-23) Up-regulation of mRNA expression of phase I enzymes on human Phase I drug metabolism array. 
The mRNA expression of a significant number of the phase I enzymes were up regulated following injection 
with the drug, compared to placebo, in the liver of chimeric mice using a human array (a). No such drug effect 
was seen in the non-chimeric mouse liver using a mouse array (b), suggesting the lack of functionality of the 














































Aldehyde dehydrogenase activity in blood 
An upregulation of aldehyde dehydrogenase enzymes (ALDH) was observed from the profiler array 
investigation. ALDH superfamily consists of 19 genes expressing key Phase1 cellular detoxification enzymes 
that oxidise various aldehydes and generate the corresponding carboxylic acid. There are three major classes 
of aldehyde dehydrogenases Class 1 and Class 3 are cytosolic and include both constitutive and induced forms 
and Class 2 is a constitutive mitochondrial form. The activity of these enzymes was tested on the plasma 
obtained from the chimeric SCID mice using a highly sensitive fluorescent kinetic assay where the limit of 
NADH sensitivity ranged between 1 to 5 pmol/µl. Acetaldehyde is oxidised by ALDH forming NADH that 
incorporates to the kit’s PicoProbe generating potent fluorescence (Ex/Em = 535/587) with sensitive detection 
of as low as < 0.05 mU ALDH activity (Figure-24). 
Despite the higher detection sensitivity of the kit used, levels of ALDH activity in the samples were extremely 
low, but detectable. While there was a slight increase in the plasma ALDH activity after multiple, compared to 

























(Figure-24) Calibration Curve for Aldehyde dehydrogenase activity assay. A slight increase in ALDH activity 
was observed in response to methandienone treatment. Increased ALDH activity levels was higher in the 





Results from this section have guided the studies that followed. First the uPA +/+ SCID mouse model and based 
on the urinary metabolite profiling of Methandienone proved to be suitable model for the investigation of 
human hepatic metabolism of any drug including ecdysteroids. Also, multiple dosing of the drug increased the 
sensitivity of detection which was applied in the experiment that followed; human hepatic metabolism of 
20HE using the uPA +/+ SCID mice. Hepatic gene expression analysis provided specific insights on the effects 
of methandienone on the expression of 84 key drug metabolising enzymes and while methandienone is widely 
investigated in the literature this provided a good tool for the investigation of 20HE effects on hepatic drug 



































3.2 Metabolism of 20HE 
3.2.1 Urinary metabolites of 20HE 
In a similar manner to the experiments conducted to investigate urinary metabolites of methandienone, 
urinary metabolite profiling was also conducted on urines collected from uPA +/+ SCID mice administered with 
multiple doses of 20HE or placebo by oral gavage. Results showed that the parent compound remained 
detectable up to 24 hours after administration in the 20HE treated group and by the end of the experiment 
on Day 4 the parent drug was not detected (Figure-25). Day 4 of the experiment represented 48 hours after 
the last 20HE administration. As expected, 20HE was not detected in the placebo treated group. 
Since the data on 20HE metabolism is sparse and the human metabolites of 20HE reported in literature by 
Tsitsimpikou et al (69) and Brandt et al.(70)  (Table-2) have not yet been validated, it was difficult to obtain 
standards of these metabolites in order to investigate their presence in the urinary profile. In addition, 
attempts in novel metabolites detection in response to 20HE is being further pursued but outside the scope 





















+EI EIC(633.3693) Scan E014 Day 0.D  Smooth 
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+EI EIC(633.3693) Scan E014 Day 3.D  Smooth 
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+EI EIC(633.3693) Scan E014 Day 4.D  Smooth 
Counts vs. Acquisition Time (min)
27 27.2 27.4 27.6 27.8 28 28.2 28.4 28.6 28.8 29 29.2 29.4 29.6 29.8 30 30.2 30.4 30.6 30.8 31 31.2 31.4 31.6 31.8 32 32.2 32.4 32.6 32.8
(Figure-25) Results from gas chromatography from chimeric mouse urine samples before and after multiple-dose administration of 20HE. 
Top row represents blank urine prior to the administration of the drug. The following three rows of chromatograms show the parent 
compound 20HE detectable 24 hours after administration. The bottom row presents the undetectability of 20HE  48 hours after last 





3.2.2 Profiler array analysis 
 
RNA extraction from Liver 
 
To investigate the hepatic gene expression profile of the drug metabolising enzymes in response to 20HE, a 
pathways specific gene expression profiler array was used. This investigation can help in identifying the 
possible reactions and modifications from phase I & II metabolising enzymes conducted to the parent 
compound by the humanised liver. Livers harvested from the animal were used for this investigation. Liver 
tissues were weighed and divided for RNA and protein extraction. Liver weights ranged from 0.4-0.7 g halved 
for RNA and protein extractions. This amount proved to be very high giving samples that are high in quantity 
and quality. All samples were diluted for downstream analyses. Results from RNA extraction are summarised 



































5 CV 7654.6 1.95 1.16 997.9 2.04 1.18 
9 CV 5124.9 2.04 1.26 1119.7 2.04 1.09 
16 CV 4887 1.95 0.65 1889.1 1.97 0.66 
18 CV 3997.5 1.89 0.56 1124.7 1.96 0.51 
7 CD 7488.7 1.92 0.84 908.9 1.96 0.73 
12 CD 7556.2 1.96 0.93 1119.1 2.02 0.87 
14 CD 6010 1.98 0.79 789.9 2 0.64 
29 CD 6952.9 2.03 1.39 1762 2.02 1.39 
19 NV 6600.9 1.97 1.24 1194.5 2 1.19 
966 ND 6753.4 1.99 1.1 1075.9 2.03 0.98 
 
(Table-14) NanoDrop RNA concentrations extracted from the harvested livers of mice treated with either 
drug of placebo. Quality ratios are also indicated where RNA is considered pure if the 260/280 ratio is ≈ 2.0 
and 260/230 ratio < 2 indicates presence of contaminants. These measurements were repeated after 1:100 













Human drug metabolism array 
As previously described PCR quality assurance was carried out using the online SA Biosciences software and 
results indicated that 15 genes were overexpressed in the 20HE treated group compared to placebo group and 
29 were under expressed (Figure-26 and 27). As expected, upregulation in the Cytochrome P450 enzymes 
including CYP11B2, CYP17A1, CYP19A1, CYP2E1 and CYP2F1 was observed. CYP19A1 (Cytochrome P450 family 
19 sub-family A member 1) is a gene that encodes the protein (enzyme) aromatase which is involved in the 
conversion of androgen hormones to oestrogen (Figure-28) (87). Another interesting Cytochrome P450 family 
of enzymes member that was also differentially expressed in response to 20HE in the drug metabolism array 
was CYP17A1 which plays an important role in the steroid biosynthesis, the clustering of the genes and the 
fold changes are shown in Figures 29 and 30.  Nitric Oxide Synthase3 (NOS3) was also upregulated in the 20HE 
treated group. NOS3 is a protein coding gene involved in several processes and most importantly it is involved 

























(Figure-26) Scatter plot of normalised expressed genes of the groups administered with 20HE and placebo 
plotted against each other. Unchanged genes are indicated in the central line surrounded by the dotted line 
representing the fold change cut-off (2.0). The upregulated (yellow) and downregulated (dark blue) present 


































(Figure-27) Volcano plot presenting significantly differentially expressed genes (p-value ≤ 0.05) plotted 



























(Figure-28) Heat map showing gene expression fold change between the 20HE and placebo group in the 
context of the profiler array layout. The array layout shows fold regulation magnitude displayed in the heat 
map. ALOX15 gene (highlighted) showed great fold change difference with significance (p < 0.05). CYP17A1 
and NOS3 genes (highlighted) were of interest due to their favourable effects of sports performance. 
Comments A, B or C given to few genes refer to cycle threshold (Ct) interpretation of the software. A; Ct is 
relatively higher in one group suggesting this gene’s expression is lower in this group and the fold change 
minimum is as reported, B; higher Ct were detected in both groups leading to inability to calculate accurate 





(Figure-29) Two-dimensional non-supervised hierarchical clustering of 20HE and placebo group gene 










(Figure-30) Fold regulation of few genes of interest detected in the human drug metabolism array. 















3.2.3 Human Excretion study 
 
Supplement analysis results 
Adding to the human metabolism of 20HE investigation and part of understanding the pharmacokinetics of 
the drug, excretion studies were conducted. Of importance is that the actual contents of supplements often 
are not reflected on the label and to overcome this the selected supplements were tested qualitatively and 
quantitively in-house to quantify 20HE content. In addition, batch-to-batch variability in the supplements was 
of concern. Therefore, consistency of supplement contents was tested using up to 5 tablets from each 




Commercial Name Quantitation per unit 
1 Turkesterone 2.3mg 
2 Ecdybolin 1.008 mg 
3 Suma root 176.17 μg 
4 Desire X 8.88 μg 
5 Immunectar 0.402 μg 
6 Natural Sterol extreme Unquantifiable 
7 Medicinal cyathula root Unquantifiable 
8 ZMA PM Undetectable 
9 Beta-X Undetectable 
10 Norateen II Undetectable  
11 Z-Force Undetectable 
12 Bio pro plus Undetectable 
13 MSB methyl plus Undetectable 
14 Power meal Undetectable 
15 Animal Stack (USA) Undetectable 
16 Promax Extreme Undetectable 
 
(Table-15) Results from GCMSMS analysis of 16 supplements that claimed to contain ecdysteroids. Only 5 
contained detectable and quantifiable amount of 20HE. Two supplements with unquantifiable amount were 









The excretion study was conducted on a single volunteer taking Turkesterone (20HE) supplement and multiple 
urine samples were collected on day 1 of the experiment up to day 5 and analysed using GCMS. The parent 
compound; 20HE was first detected after 2 hours post administration with maximum level detected at 4-5 
hours post administration.  The detectability of the parent compound remained up to 48 hours post 
administration of the mislabelled supplement Turkesterone which upon analysis was found to consist of 20HE 
(Figure-31a). After the washout period excretion study was repeated using Desire-X supplement which 
contained lesser concentration of 20HE (8.8 µg) where the parent compound remained detectable up to only 























(Figure-31) Urinary excretion profile of 20HE from a single volunteer using GCMS analysis. y-axis represents 
the abundance which based on signal intensity of the 20HE graphed against time (x-axis). Panel (a) shows the 
excretion profile of 20HE after administration of Turkesterone supplement and maximum abundance of 20HE 
was observed 4-5 hours post administration. Panel (b) presents 20HE excretion profile after the administration 
of Desire-X supplement containing lower level of 20HE where it was observed that 20H was detected up to 36 







3.3 Discussion of results 
 
Urinary metabolites of Methandienone 
In this study the principals of pharmacokinetics were applied to investigate metabolism and excretion of 
Ecdysteroids. Firstly, the ability of the selected humanised liver murine model to generate the human hepatic 
metabolites of the gold standard doping agent, Methandienone, was determined. Human hepatic drug 
responses were compared using data acquired from human and mouse drug metabolism arrays. The 
experiment was setup to allow the investigation of the sensitivity of the model towards a single dose 
administration in comparison to multiple dosing and its effect on increasing the sensitivity of detection of 
human hepatic metabolites of the drug. This study provided an indication of successful in-house detectability 
of the expected reported metabolites of Methandienone using the analytical method developed and approved 
by the world anti-doping agency (WADA) to be used for the detection doping incidents from human urine 
samples obtained from athletes.   
 
Profiler array analysis 
Mouse phase I drug metabolism enzymes profiler array was used to investigate the hepatic response of the 
residual mouse liver in the chimeric mice and this was compared to human phase I drug metabolism profiler 
array. This investigation further confirmed the suitability of the model for the detection of 20HE metabolites 
and lead to the next aim of this project to investigate the human hepatic metabolism of 20HE using the uPA 
+/+ SCID mice model. 
 
Aldehyde dehydrogenase activity in blood 
After the global upregulation of ALDH family of enzymes observed in the profiler array analysis further 
confirmation of its activity in the blood was investigated. No significant changes were observed in the plasma. 
The most apparent limitation faced in the investigation was the use of plasma and for future investigation 









Urinary metabolites of 20HE 
Results from the first experiment using uPA+/+ SCID mice to generate human hepatic metabolites of 
Methandienone provided a solid ground to build the next experiment using the same murine model for the 
detection of human hepatic metabolites of 20HE using multiple dosing which increased the sensitivity of 
detection in the first experiment. One of the drawbacks of this model was the small volume of urine collected 
from these mice throughout a 24hours period.  
 
Profiler array analysis 
Hepatic gene expression profile after administration of 20HE was investigated using human drug metabolism 
profiler array. Results indicated the upregulation of 15 genes and down regulation of 29 in the 20HE opposed 
to the placebo group. Genes involved in steroidogenesis regulation and vascular function (CYP17A1 and NOS3 
respectively) that were significantly differentially expressed were of interest. Since 20HE has been added in 
the WADA monitoring list due to its purported these genes presented basis for future studies in the context 
of doping and performance enhancement.  
 
Human Excretion study 
Further investigation of 20HE excretion was conducted on one individual using selected 20HE containing 
supplement and another that does not contain 20HE.   To overcome the extensive process of ethical 
restrictions in this study, a dietary supplement containing 20HE was used, since these supplements reach the 
market directly from manufacturers without the need of approval from any regulatory body; as is the case for 
drugs.  20HE was first detected 2 hours after administration with peak detection intensity between 4-5 hours 
which decreased but remained detectable up to 48 hours. Lower concentration showed 20HE excretion period 
up to only 36 hours. These parameters are key in developing methods to detect the use of this compound in 


























Dietary supplements intake in addition to being globally wide spread, its use is prevalent among elite athletes. 
Meta data analysis studies revealed that elite athletes use dietary supplement more often than recreational 
athletes (11). Reasons behind this prevalence of use is that among athletes include compensation for specific 
deficiencies such as iron or vitamin E where it was reported that female athletes often use the former while 
male athletes consume the later or protein and creatine (11). Other reasons relate to sport performance 
enhancement by increasing muscle recovery and training effectiveness and reducing risk of muscle injury as 
explained by the international Olympic Committee IOC in the supplement consensus statement published in 
2017 (22). Out of 16 supplements claiming having 20HE, two were chosen for this this study based on their 
concentration of 20HE or lack thereof (Desire-X and Z-Force respectively). A cohort of recreational athletes 
was recruited and their anthropometric, blood pressure and aerobic fitness measurements were recorded 
before and after 2-months intervention with the supplements. Measures of aerobic fitness were further 
investigated in-vitro testing mitochondrial membrane potential after overnight treatment with different 
concentration of 20HE in human skeletal cells myoblasts and preadipocytes. Transcriptome and proteomics 


















4.1 Human Studies  
4.1.1 in-vivo studies 
Previous reports showed the anabolic activity of 20HE when taken at high concentrations (54-56,66). Here the 
focus was on supplement derived 20HE intake at a lower concentration using 20HE containing supplement 
compared to a supplement that does not contain 20HE. This supplement though it is recommended by the 
manufacturer to take 2 to 3 tablets per day, the total concentration was considered lower than the levels that 
were reported as anabolic. This study provides insight on 20HE effects at low non-anabolic concentration on 
body composition, blood pressure, blood chemistries and aerobic fitness. 
 
4.1.1.1 Body composition  
Changes in Body Composition of the recruited recreational athletes were measured before and two months 
after the intervention with 20HE supplement and is summarized in (Table-16). Though the two groups were 
not age matched, this was not considered a limitation since the comparison was conducted before and after 
the intervention in the same individual and no comparison between the groups was conducted. A slight 
increase in body weight in the 20HE supplement group was observed after the intervention explained by 
increase in muscle mass with actual decrease in fat mass (Table-16). This increase is behind the noticeable 


















































































(Table-16) Whole body segmental analysis measured on recruited recreational athletes before and after 
supplement intervention using. No significant changes in  muscle mass and fat mass in the 20HE group were 


















Blood Pressure measurements were recorded before and after the intervention (Table-17).  Significant 
decrease in the diastolic blood pressure (p=0.04) was observed after 20HE supplement intervention. No other 
significant changes were noted. Individual changes in measures of blood pressure before and after the 





Desire-X (20HE) (n=7) Z-Force (n=6) 



































(Table-17) Changes in blood pressure prior to and after 20HE or placebo supplementation. Significance was 
observed only in the diastolic blood pressure of 20HE-supplement taking group with p-value= 0.05. Results 











   
  
 
(Figure-32) Effect of Desire-X; a 20HE containing supplements on blood pressure. Recorded blood pressure 
measurements of systolic (SBP) (top panel) Diastolic (DBP) (middle panel) and mean arterial (MAP) (bottom 


















































































Haematology report from Sysmex indicated a significant drop in RBC count (p=0.01) thus the significant drop 
in haematocrit to 41.5% (p=0.04). This was also observed in platelets count but failed to reach significance 
(p=0.07). Creatinine levels were significantly elevated after the intervention with 20HE supplement (p=0.03) 
which may indicate lower glomerular filtration rate in the kidney. Changes in systemic glucose and lipids were 
recorded and summarised in (Tabl-18). For the group consuming 20HE containing supplement (Desire-X) a 
marginal decrease in glucose, HDL cholesterol and triglycerides were observed but non reached significance. 
Similar profile was observed in the placebo supplement group (Z-Force) for the glucose and total cholesterol. 
Interestingly, significant decrease in the healthy cholesterol (HDL-Cholesterol) was recorded in response to Z-
Force p= 0.03 (Table-18).  
 
 
Supplement Desire-X (20HE) Z-Force 





















































(Table-18) Recorded systemic glucose and lipids for both groups. Glucose levels were marginally reduced in 
both groups and comparing both groups no other significant changes were observed. Significant decrease in 





4.1.1.3 Aerobic fitness 
Basic level of aerobic fitness was recorded during the initial visit and then recorded again after the 
intervention. Results are summarised in (Table-19). Improvements in aerobic indices were seen after the 
intervention with 20HE supplement. A 1.10 fold increase in VO2max was observed after 20HE intervention 
(Figure-33) and the velocity at VO2  (vVO2 ) which refers to the pace at which the VO2max was achieved was also 
improved after the intervention with 20HE supplement. Also, metabolic equivalent (MET) was increased after 
the intervention with 20HE containing supplement meaning the energy expenditure has increased indicating 
increased aerobic fitness. These indices of aerobic fitness were actually decreased in the placebo supplement 
group. 
 
Maximum voluntary ventilation MVV is a measure of gas exchange that describes the air volume an individual 
breathes as quickly and deeply as possible in a given time frame. This measure reflects ventilatory function 
while respiratory quotient RQ represents the respiratory exchange ration RER which during resting state is 
equal to the RQ. RQ value indicates the energy consumed for metabolic processes where when carbohydrates 
are the primary source of energy for the metabolic process RQ value is equal to 1 and a value of less than 1 
indicates a mixture of carbohydrates with proteins or fat (RQ=0.8 or 0.7 respectively) (88). MVV and RQ 
measurements were significantly reduced (p <0.01) after the intervention with 20HE while in the placebo 
supplement group MVV was significantly reduced (p <0.01) and RQ was also reduced without statistical 
significance.   
 
Aerobic exercise directly relates to aerobic respiration process in the mitochondria for the continuous energy 
generation. The mitochondrial respiration is indicated by the polarisation within the compartments of each 















(Figure-33) Change in VO2max before (V1) and after (V2) intervention with 20HE supplement. One data set 




















Variables Visit 1 Visit 2 p-val Visit 1 Visit 2 p-val 

























































(Table-19) Recorded measures of aerobic fitness before and after supplement intervention.  Overall 
improvements in aerobic indices after 20HE supplement intervention were observed. Data are shown as mean 











4.1.2 Human in-vitro study: Effect on mitochondrial membrane potential (MMP) 
In this section the aim was to investigate aerobic respiration of mitochondria in response to 20HE since 
improvements in aerobic fitness indices were observed after in-vivo investigation. Increasing concentrations 
of 20HE were used to treat human preadipocytes and myoblasts to identify the effect of 20HE on 
mitochondrial polarisation or mitochondrial membrane potential (MMP).  
 
4.1.2.1 Preadipocytes  
 
Cell culture optimisation 
Lean human White Preadipocytes (HWP) from subcutaneous depots at passage 6 (P6) were resurrected 
according to the manufacturer’s protocol and seeded in two T25 flasks. At 80% confluence the cells were 
passaged to two T75 flasks. Cells were growing at a slower rate than before the passage. It was thought to be 
due to passaging at 80% confluence or the low numbers of cells that were seeded in each flask. Juxta-
positioning of the cells may have been an important factor and due to the unusual slow growth of cells, they 
were trypsinised back to two T25, using 3mL trypsin (just enough volume to cover all surface area of the flask) 
and then incubated at 37⁰C with 5% CO2 for 2-5 minutes. It was observed that after 3 minutes all cells were 
in suspension. All 6mL of the trypsinised cells from both flasks were added to 6mL of growth media in 15mL 
falcon tube. Cells were pelleted by centrifugation at 1200 RPM for 5minutes at room temperature and all 
media and trypsin was pipetted out. Cells were washed with 5 mL of media and centrifuged at the same 
conditions to remove any traces of trypsin. Cells were then resuspended in 4mL media and seeded into two 
T25 flasks. Unfortunately, cells did not survive the transfer to the T25 (Figure-34). Lessons learnt from these 
initial experiments were 1) Cell number should be adequate when seeding on the first day, 2) cell-to-cell 













A new aliquot of primary human white preadipocytes (HWPA) was resurrected into T-25, since the previous 
aliquot had very low cell counts, and grew very poorly during a three-week period. Media was changed 24 
hours after resurrection. There appeared to be more cells that had adhered compared to the previous 
attempt, which were at about 20% confluent 24 hours after seeding. Following this, cells were observed every 
day and the media changed every 48 hours. Cells were about 30% confluent which was still relatively slow. A 
possible explanation for this could be that these were commercially available primary cells, with very limited 
passaging capabilities. Further, the donor of these cells was a lean Caucasian middle aged female (45 years). 
Cells from older subjects often lose their plasticity and ability to replicate sooner than those from young 
donors. Cells were at 30% confluence and apparently were senescent but were still maintained to see if they 
would proliferate. Results from these cells may understandably be unreliable. All these initial aliquots were 
resurrected in T25 flasks but after a month of senescent cells and slow proliferation; cells were resurrected in 


















































(Figure-34) Progression of preadipocytes growth. There were major difficulties in the initial studies with the 
growth of preadipocytes. Cells 24hours after seeding on T75 flask (a), cells at 80% confluence (b) which were 
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(Figure-35) Cells resurrected and grown on 6-well plates to overcome the low viability rate after resurrection 
in T25 flasks. Cells 24 hours after initial resurrection and seeding (a) and observed cell growth 48 hours after 









Series of experiments were carried out to test the best seeding densities for the microscope coverslips in order 
to commence the planned confocal studies. The first attempted seeding density was 1500 cells and after 
overnight incubation at 37⁰C/5% CO2, cells were sparse and mainly seen at the edges of the cover slip. This 
was probably due to the low number of cells seeded and the positioning of the cover slip inside the 24-well 
plate. On the second attempt cells were seeded on three additional cover slips each at density of 5000 cells 
which proved to be too high though individual cells were successfully visualised, the fields were overcrowded. 
Thus, the next batch of coverslips were seeded with 2500 cells which was the best seeding density and it was 
used for the experiments that followed as standard procedure.  
 
Confocal imaging 
An initial experimental plan included the cells grown on coverslips for confocal studies and in 6-well plates for 
RNA, DNA and protein extraction. Three coverslips were seeded with preadipocytes and after overnight 
incubation one coverslip was treated with the highest dose of 20HE (10µM) overnight while media was 
changed for the remaining two coverslips. All coverslips were investigated under confocal microscopy after 
TMRE staining and the delta change in the intensity was recorded after the addition of FCCP (Figure-36). The 
initial studies showed that the TMRE concentrations used were able to capture good quality images of the 
mitochondria, with increased intensity, suggesting coupled mitochondria. After the establishment of the 
optimal conditions additional experiments were conducted with treatment with 0, 1 ,5 and 10 µM 
concentrations of 20HE.Results from the combined protocol for the extraction of RNA, protein and DNA from 

















Sample Sample Type Conc. (ng/µL) 260/280 260/230 
C1 DNA 62.5 1.49 1.29 
C2 DNA 60.8 1.44 0.91 
C3 DNA 28.5 1.48 0.23 
D1 DNA 54.6 1.45 1.15 
D2 DNA 37.5 1.46 1.08 
D3 DNA 26.5 1.55 1.04 
Sample Sample Type Conc. (µg/mL) A280 260/280 
C1 RNA 1639 1.94 1.03 
C2 RNA 1105.7 1.76 0.44 
C3 RNA 1510.5 1.89 0.77 
D1 RNA 996.3 1.72 0.38 
D2 RNA 990.7 1.72 0.38 
D3 RNA 1516.3 1.88 0.73 
Sample Sample Type Conc. (µg/mL) A280 260/280 
C1 Protein 48 0.048 0.60 
C2 Protein 73 0.073 1.94 
C3 Protein 366 0.366 1.29 
D1 Protein 280 0.280 1.09 
D2 Protein 638 0.638 0.99 
D3 Protein 624 0.624 0.90 
 
(Table-20) Results of DNA, RNA and protein extraction from cells using a combined protocol. The top panel 
shows the quantity and quality of the DNA and RNA, and the bottom panel the protein, extracted ascertained 
















 (Figure-36) Visualisation of initial confocal studies conducted on preadipocytes before and after adding 
MMP uncoupler. Preadipocytes were seeded on coverslips and treated with 10µM 20HE (top panel) or vehicle 
(bottom panel) for 24 hrs. Delta change was calculated based on the intensity before (left) and after (right) 
treatment with FCCP where the calculated delta changes after 20HE treatment was 37.28 and 7.39 for the 







Experiments with increasing doses of 20HE 
The same format used in the previous section was conducted to test the effect of 20HE treatment on MMP at 
doses of 0, 1, 5 and 10 µM. Results from two experiments conducted on preadipocytes each consisting of four 
coverslips treated with 0, 1,5 & 10 µM 20HE overnight are shown in (Figure-37). No significant change was 
observed between the untreated and 1µM treated preadipocytes in the delta change of MMP intensity after 
the addition of FCCP (Figure-38).  Significant increases in delta change were observed in the 5 & 10µM treated 





(Figure-37) Preadipocytes confocal results averaged from two experiments. Observed difference in 
mitochondrial membrane potential after treatment with 20HE. Significant increase in MMP in the 5 and 10 
µM treated cells compared to the untreated cells. No significant difference in MMP was observed after 
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(Figure-38) Effect of FCCP; mitochondrial membrane potential uncoupler on TMRE stained preadipocytes. Preadipocytes before (left) and after (right) adding FCCP. 
Maximum amplitude on intensity was recorded from the field before adding FCCP and then the minimum amplitude recorded after the addition of FCCP was 





4.1.2.2 Myoblasts  
 Seeding density optimisation  
To begin investigating MMP on myoblasts, seeding density optimisation study similar to the preadipocytes 
optimisations were conducted. chamber slides were also tested for suitability in this section due to their 
practicality when compared to coverslips. 
 
Use of cover slips compared to 4-well chamber slides 
Seeding density optimisation on the 4-chamer slide showed that seeding at a density of 20,000 cells per 
chamber yielded fields that were too crowded causing cells to overlap. The best seeding density was at 10,000 
cells per chamber (Figure-39). Cells were also seeded on cover slips for comparison reasons of both slide types 
(coverslips or chamber slides) according to the protocol detailed in previous section. No differences in 
visualization of cells were observed (Figure-40). Advantages of chamber slides included: practicality, ability to 
culture the cells for few days on the slides which meant more experiments can be conducted per week and 
the ability to differentiate the cells when they reach confluence on the slide without the need to trypsinise 
and seed into coverslips. The main disadvantage or difficulty was faced during the addition of FCCP where the 
well walls prevent the proper placement of the pipette tip especially since FCCP was added in a relatively small 
amount (10μl) in comparison to TMRE stain (500μl). Other parameters such as the density of glass when using 
coverslips placed on a slide in comparison to the density of glass of the chamber slide, had not have any 







































(Figure-39) Myoblasts seeding density optimisation in 4-well chamber slide. 5000 cells (a), 10,000 (b) cells, 
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(Figure-40) Comparison on visualisation of myoblasts grown on cover slips (left) and 4-well chamber slides (right). No visual differences were noticed, comparing 










Optimising the use of DMEM as a replacement of manufacturer’s recommended media revealed that 
myoblasts were able to grow in both media but in a slower rate in DMEM up to 4 days where the cells growing 
in DMEM were senescent and by day 8 cells were dead and the experiment was terminated (Figure-41). As a 



















































(Figure-41) Comparison of myoblasts growth dependent on media. DMEM (Left) [(a), (c), (e)] and SKGM 
recommended media (right) [(b), (d), (f)] were compared under light microscopy (Leica). Pictures were taken 
after a day (a) and (b), 4 days (c) and (d) and at the end of the experiment at 8 days after seeding (e) and (f). 
 
 
(a)                                                                  (b) 
(c)                                                                  (d) 




Myoblasts confocal imaging  
Results from four experiments each consisting of four coverslips treated with 0, 1, 5 & 10 µM 20HE overnight 
and investigated under confocal microscopy are summarised in (Figure-42). Similar results of those reported 
in preadipocytes were also observed in myoblasts. Significant increase (p=0.01) in the delta change in the 5 & 
10 µM treated cells in comparison to the untreated and cells treated with 1µM 20HE. Delta change is the 
difference in signal intensity of the TMRE stain detected by the confocal microscopy system between the same 
field before and after adding FCCP. Increased signal intensity is indicative of increased polarity between the 
compartments of mitochondria and this membrane potential is harnessed for ATP synthesis. Adding FCCP 
allows the free transport of the protons between mitochondrial compartments diminishing polarity and signal 
intensity of the TMRE stain. 
Mitochondria membrane potential investigation as an indicator of polarised active mitochondria revealed that 
20HE has significant effects on mitochondrial respiration in both preadipocytes and myoblasts. Further 





















(Figure-42) Mitochondrial membrane potential differences after treatment with 20HE. A significant increase 
in the Δ change of recorded intensity after treatment with 10µM of 20HE in comparison to the vehicle treated 
cells (p=0.01) which means significant increase in mitochondrial function in response to higher doses of 
















4.2 Molecular mechanisms- Omics approach 
The suffix omics refers to comprehensive investigation. It is applied to genes (Genomics), proteins 
(Proteomics) or phenotypes (Phenomics) among other studies. After the targeted and specific effects of 20HE 
that were reported in this study, an omics approach was conducted investigating total effects of 20HE on the 
proteome (protein profile) and transcriptome (expressed genes profile). Protein and RNA extracted from the 
humanised SCID model treated with 20HE were used for the omics investigations. 
 
4.2.1 Proteomics 
4.2.1.1 Protein extraction and concentration estimation 
 Proteins were extracted by homogenising the liver tissue in RIPA buffer and concentrations were estimated 
using BCA colorimetric assay (Figure-43). Proteins from all samples had concentrations that were too high, and 
the assay was not able to provide reliable estimation. Thus, protein samples were diluted twice, and 
concentration estimation was repeated after 1:500 dilution (Table-21).  
4.2.1.2 Proteome analysis using the ELITE Orbitrap LC/MSMS 
Data analysis was conducted on the raw files and .msf files created from Proteome Discoverer software. Scans 
from raw files were viewed using RawMeat V.2 where full scans represent parent peptides and MSMS scans 
show more peaks within the parent compound detected and the numbers of these scans for one sample 
consisting of 8 fragments as an example is reported in (Table-22). Trypsin/lysin digestion controls were studied 



















(Figure-43) Calibration curve of standards for the estimation of protein concentration. BSA was used as the 


























































5 12 8 0.71 1.41 
7 14.1 5.9 0.60 1.21 
9 13.1 6.9 0.65 1.30 
12 14.3 5.7 0.59 1.19 
14 16.4 3.6 0.52 1.03 
16 12.3 7.7 0.69 1.38 
18 11.7 8.3 0.72 1.45 
19 19.2 0.8 0.44 0.89 
29 13.4 6.6 0.63 1.26 
966 14.8 5.2 0.58 1.15 
 
(Table-21) Results of protein concentration estimation was done using Pierce BCA protein assay kit. The 
















Raw file  
Sample9 




Fragment 1 4359 10915 
Fragment 2 3952 12900 
Fragment 3 2836 18145 
Fragment 4 3189 16433 
Fragment 5 3618 14722 
Fragment 6 4220 11741 
Fragment 7 5518 7811 
Fragment 8 6190 5922 
 
(Table-22) Full Scans of parent peptides detected using the LCMS and MS2. Full scans present the number of 
parent peptides detected in the first MS scan and these were further analysed with a second MS giving rise to 


















(Figure-44) Charge distribution of N-Terminus. For the digestion to have worked the charge of 2 is expected 
to indicate acceptable quality of digestion. Most of the peptides attained this quality. This graph presents the 













4.2.1.3 Proteomics data analysis  
Output files from proteome discoverer were analysed as detailed in methods using excel. 1664 proteins were 
quantified and detected in both 20HE and placebo group where significant differences in abundance were 
found in 32 proteins. 70 proteins were specific to the 20HE treated group whereas 68 proteins were specific 
to the vehicle treated group. Computational predictions based on the proteins that had p-value of less than 
0.05 showed possible interactions between these proteins using STRING which is a web-based search tool 
identifying protein-protein interactions (91) (Figure-45).  
The 70 proteins that were only detected in the 20HE group were also analysed on STRING and some of the 
enriched pathways are shown in (Figure-46). Metabolism and metabolism of proteins pathways were enriched 
after 20HE treatment according to the data from Gene Ontology and Reactome. 
Looking at the 68 proteins uniquely detected in the placebo group one could cautiously presume possible 
suppression of these in response to 20HE. Utilising STRING, 54 of the 69 proteins were shown and enriched 
pathways are presented in (Figure-47). Though many of the enriched pathways in the placebo group are not 
unique to the group and also were found in the 20HE or the shared protein analyses, the proteins detected 
within the pathways differ. Which indicate the enrichment of alternate pathways in response to the treatment. 
For example, the Reactome metabolism pathway was enriched in all 3 analyses; shared proteins among the 
groups, proteins specific to 20HE and protein only detected in the placebo group (Figures-45,46 and 47). 
Proteins detected in the metabolism pathway in the first group included: RPS10, ACLY, PGD, DPYS, CSNK2B, 
PP2R1A, PCCA, UGT1A4, CPT1A and APOA1. While the 20HE group proteins within the same pathway included: 
GBE1, GPHN, RPL23A, RPS20, PON3, RAN, GSTO1, PSMC3, PAICS, ETFA, LDHB, AASS, DECR2 and CMPK1. Lastly, 
proteins detected within the pathway in the placebo group included: ACSM3, SULT1A3, CRYM, UQCRC2, ETFA, 












(Figure-45) Protein-protein interaction network.  The interactions between the identified 32 proteins that 
were significantly altered in abundance between the 20HE and placebo treated groups were generated using 
STRING. Colour codes within each node represents the protein involvement in the specified enrichment 
pathways from GO biological processes and Reactome (91).  
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(Figure-46) Specific proteins abundant in the 20HE treated group. Figure shows the interactions network 
according to enriched pathways against Gene ontology and Reactome databases. Colour codes within each 
node represents the protein involvement in the specified enrichment pathways from GO biological processes 
and molecular functions and Reactome (91).  
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(Figure-47) Enriched pathways according to input proteins specific to placebo group. Proteins list was 
analysed using STRING against Gene Ontology (GO) and Reactome databases (91). Colour codes within each 
node represents the protein involvement in the specified enrichment pathways. 
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4.2.2 Transcriptome analysis  
The second omics approach utilised was transcriptome analysis where extracted RNA from the humanised 
SCID model treated with 20HE or placebo was used. 
4.2.2.1 RNA sample preparation  
Results of quality check using the NanoDrop after in-vitro transcription and fragmentation of all samples in 
triplicates are summarised in (Table-23). Since the quality of the input RNA was good all downstream reactions 
yielded sufficient amounts which were quantified as per manufacturer’s recommendations after the overnight 
in-vitro transcription (IVT) and single stranded cDNA synthesis. 
4.2.2.2 Results from in-house Data Analysis 
Analysis was conducted using TAC 4.0 software and showed 37 differentially expressed genes (Table-24) when 
comparing 20HE treated group with vehicle treated group which is illustrated in (Figure-48). Expression analysis 
were set at fold change < -2 or > 2 and p-value≤ 0.05 was considered significant at gene level. Of these 37 
genes, HES1 gene which is a transcription factor that prevents transcription was significantly downregulated 
with p-value of 2.27E-05, it is a negative regulator if myogenesis adding to the data indicating increased muscle 
mass in response to 20HE treatment. This data, though interesting, it comes from a compromised mice model 



















after IVT (µg) 
Amount 
required (µg) 
cDNA Yield after 2nd cycle 
ss-cDNA synthesis (µg) 
Amount 
required (µg) 
5 A1 1784.9 15 490.0 5.5 
A2 1301.4 15 490.0 5.5 
A3 1431.8 15 390.0 5.5 
7 A4 1194.8 15 398.4 5.5 
A5 1239.6 15 63.6 5.5 
A6 1172.9 15 403.8 5.5 
9 A7 484.5 15 234.7 5.5 
A8 1128.2 15 400.4 5.5 
A9 1359 15 397.1 5.5 
12 A10 777.1 15 414.3 5.5 
A11 668.2 15 352.8 5.5 
A12 711.5 15 347.9 5.5 
14 B1 1045.6 15 738.3 5.5 
B2 741.8 15 356.2 5.5 
B3 1396.8 15 391.5 5.5 
16 B4 646.9 15 377 5.5 
B5 760.1 15 341.4 5.5 
B6 641 15 350.8 5.5 
18 B7 1282.8 15 434.5 5.5 
B8 1163.4 15 403.3 5.5 
B9 459.2 15 164.3 5.5 
19 B10 920.3 15 389.2 5.5 
B11 691.6 15 384.5 5.5 
B12 651.7 15 356.7 5.5 
29 C1 1338.6 15 488.4 5.5 
C2 788.5 15 431.2 5.5 
C3 1099.6 15 410.2 5.5 
966 C4 1080.6 15 430.3 5.5 
C5 1224.6 15 406.9 5.5 
C6 1181.5 15 437.6 5.5 
(Table-23) Quality check of cRNA & cDNA concentrations. Samples were measured using NanoDrop during 




Gene Symbol 20HE Avg (log2) Vehicle Avg (log2) Fold Change p-val 
WNK1 4.65 3.61 2.06 0.05 
STK36 3.66 4.73 -2.1 0.05 
G6PC 13.4 12.26 2.2 0.04 
ODF2L 5.39 4.35 2.06 0.04 
DIP2C 4.37 5.45 -2.11 0.03 
MRPL42 7.27 8.42 -2.23 0.03 
NAT6 5.6 4.56 2.07 0.03 
PPM1D 6.38 5.06 2.5 0.03 
HSPA1B; HSPA1A 10.14 11.71 -2.96 0.03 
DUSP1 10.08 8.97 2.16 0.03 
RANBP1 6.9 7.96 -2.08 0.02 
GATS 5.51 4.51 2.01 0.02 
CXXC1 3.94 4.97 -2.05 0.02 
HPS5 9.26 8.14 2.17 0.02 
MYSM1 6.99 5.92 2.11 0.02 
GMNC 4.48 5.54 -2.08 0.01 
REPS2 5.51 6.63 -2.17 0.01 
MANF 4.59 5.61 -2.02 0.01 
MT1L 15.21 14.2 2.02 0.01 
CD180 4.27 3.26 2 0.01 
POGZ 5.32 4.28 2.06 0.01 
MYO5A 3.85 4.91 -2.08 0.01 
BLZF1 6.09 7.1 -2.01 0.01 
BBX 5.74 7.02 -2.43 0.01 
PGD 4.79 5.98 -2.28 <0.01 
MCM4 5.68 6.7 -2.02 <0.01 
KARS 8.41 9.43 -2.02 <0.01 
ZNF573 5.29 4.27 2.02 <0.01 
PTPRO 3.87 2.4 2.76 <0.01 
INCA1 5.02 3.91 2.16 <0.01 
HNRNPCL3 4.3 3.28 2.03 <0.01 




ZDHHC18 7.31 6.16 2.22 <0.01 
ZNF420 4.6 5.71 -2.15 <0.01 
STIP1 7.4 8.64 -2.36 <0.01 
HES1 6.68 8.24 -2.95 <0.01 
HERPUD1 10.51 12.24 -3.32 <0.01 
G6PC 13.4 12.26 2.2 0.0434 
MRPL42 7.27 8.42 -2.23 0.0294 
HPS5 9.26 8.14 2.17 0.0155 
MANF 4.59 5.61 -2.02 0.0136 
CDC42EP4 4.31 5.32  -2.01 <0.01 
ZNF420 4.6 5.71 -2.15 <0.01 
HES1 6.68 8.24 -2.95 2.27E-05 
HERPUD1 10.51 12.24 -3.32 3.85E-07 
 
(Table-24) Differentially expressed genes between 20HE and vehicle treated groups. Data were created using 
TAC 4.0 software. Many of these genes express key functions such as the G6PC gene expresses a key enzyme 
for glucose homeostasis, HES1which is a negative regulator of myogenesis and MRPL42 that plays a role in 




























(Figure-48) Volcano plot of altered genes after 20HE treatment. Number of differentially expressed genes; 





Gene table without any filters applied, showing all genes detected from the transcriptome array was exported 
and 230 human liver drug metabolism genes were investigated. Of these 230 genes only 9 were found to be 
significant with p-value ≥0.05 summarised in (Table-25). In addition, 104 mitochondria related genes were 
investigated and only three were found to be significant while other few showed no significance in differential 



















Phase1 3.88 4.64 -1.69 0.0411 CYP17A1 cytochrome P450, family 17, 
subfamily A, polypeptide 1 
8.62 9.62 -1.99 0.0545 CYP1A1 cytochrome P450, family 1, subfamily 
A, polypeptide 1 
6.25 5.86 1.32 0.0227 GZMB granzyme B 
4.59 3.96 1.54 0.0578 ALDH1A2 aldehyde dehydrogenase 1 family, 
member A2 
8.92 9.32 -1.32 0.0432 ALDH5A1 aldehyde dehydrogenase 5 family, 
member A1 
Phase2 5.12 4.61 1.43 0.0251 IFT22 intraflagellar transport 22 
3.25 3.7 -1.37 0.0251 GAD2 glutamate decarboxylase 2 
2.39 2.82 -1.35 0.0278 LPO lactoperoxidase 
3.04 2.58 1.38 0.0407 NOS3 nitric oxide synthase 3 (endothelial 
cell) 
5.58 5.16 1.34 0.0257 NQO1 NAD(P)H dehydrogenase, quinone 1 





4.22 3.62 1.51 0.0256 ATP4A ATPase, H+/K+ exchanging, alpha 
polypeptide 
8.85 9.16 -1.24 0.0166 NDUFB8 NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 8, 19kDa 
 
7.27 8.42 -2.23 0.0294 MRPL42 mitochondrial ribosomal protein L42 
(Table-25) Differentially expressed genes categorised according the proteins expressed. Enzymes involved in 








4.2.3 Functional Enrichment analysis (pathway analysis) 
 
Datasets obtained from different omics approaches are generally large and overwhelming. An important tool 
to interpret such data is pathway analysis (PA), also known as functional enrichment analysis. Instead of looking 
at these datasets -or in this study gene lists- as a large number of genes in isolation of their biological context, 
pathway analysis allows easier detection of related genes that can be differentially expressed in treatment 
group when compared to control (89). Biological causes are more easily explored when examining gene 
expression within these pathways. 
4.2.3.1 Transcriptome  
Initial PA was conducted using the TAC 4.0 software. The most significant hit found was the VEGFA-VEGFR 
signalling pathways (Figure-49). This in part could be due to the significant FDR p-value of the NOS3 gene.  
 
 
(Figure-49) Effect of 20HE on the expression of the VEGFA-VEGFR signalling pathway components. NOS3 
(circled) was reported as significant in the transcriptome data. The red and blue colours in the genes represent 
over and under representation of the gene respectively in the treatment group compared to control. Pathway 







Further PA analysis was done in collaboration with Qatar Computational Research Institute and exported gene 
list was looked at against KEGG pathways. Many interesting pathways revealed significance. These included 
steroidogenesis, hypertrophy\anabolic, mitochondrial and ER stress pathways. These pathways were briefly 




Pathway analysis showed that steroidogenesis pathway was significant with p-value=0.01 and one of the genes 
within this pathway that was found significantly downregulated was CYP17A1 in the 20HE treated group 
compared to the placebo group (Figure-50).  It Plays an important role in steroidogenesis and it also controls 
the levels of mineralocorticoids which influence blood pressure, glucocorticoids involved in immune and stress 
responses, and androgens and oestrogens. 
 
 
(Figure-50) Steroidogenesis pathway.  CYP17A1 (circled) gene was significantly downregulated in the 20HE 
treated cohort and this downregulation affected downstream reactions. The red and blue colours in the genes 
represent over and under representation of the gene respectively in the treatment group compared to control. 






Another significant pathway reported was the anabolic pathway and according to the data from the 
transcriptome analysis the gene Myogenin (MYOG) which is a transcriptional activator that functions in  
promoting the transcription of  genes that are muscle-specific taking part in the hypertrophy/anabolic pathway 
and it was significantly downregulated (Figure-51). This is in line with reports of increased muscles mass in 




(Figure-51) Hypertrophy/Anabolic pathway showing MYOG gene (circled) that was significantly 
downregulated in response of 20HE treatment indicated by the red and green colour respectively in the PA 
analysis. The red and blue colours in the genes represent over and under representation of the gene 






Mitochondria related pathway 
In the mitochondria related pathway, it was found that ATP4A (ATPase H+/K+ Transporting Subunit Alpha) 
proton pump was significantly downregulated in response to 20HE treatment (Figure-52). This enzyme 
catalyses ATP hydrolysis coupled with hydrogen and potassium ions across plasma membrane it aids in 
maintenance of acidic environment in the stomach. 
 
 
(Figure-52) Genetic pathway which relates to the mitochondrial function where ATP4A (circled) was 
significantly downregulated. It harnesses the energy from ATP hydrolysis for the transport of H+ and K+ ion 
against their concentration’s gradient. The red and blue colours in the genes represent over and under 
representation of the gene respectively in the treatment group compared to control. Pathway analysis 









Endoplasmic reticulum stress pathway 
One of the most repeatedly found genetic functions from the transcriptome data was relating to Endoplasmic 
Reticulum stress. This was reported in the ER stress pathway (Figure-53) where many genes within the pathway 
were significantly differentially expressed including HERPUD1 which plays a role in responses to stress induced 
by misfolded proteins. Heat-shock cognate protein expressed by HSPA8 was also significantly upregulated and 
was reportedly functions in facilitating correct folding of proteins. 
 
 
(Figure-53) ER stress pathway where many significantly differentially expressed genes were found including 
HERPUD1, PPP1R3C, HSPA8, DNAJA1 and MAP3K7IP2 (circled).  The red and blue colours in the genes 
represent over and under representation of the gene respectively in the treatment group compared to control. 






4.2.3.2 Combined functional enrichment analysis on the proteome and transcriptome data 
 
Protein gene IDs were obtained using uniport.org database converting protein accession number to their 
respective gene names. From the transcriptome data, significantly differentially expressed genes were 
compared to the protein list that is shared between the 20HE and placebo treated groups. Protein accession 
numbers, which are unique identifiers, were converted to their respective genes using uniport.org database 
(93) and then compared to the transcriptome data. 714 genes were matched from the transcriptome 
(significantly differentially expressed among 20HE vs. placebo) and proteome analysis. These were analysed 
using gProfiler -another web-based functional enrichment analysis tool, also known as over-representation 
analysis- showing possible enriched pathways and physiological functions based on the input gene list (92). 
Enriched pathways were identified with significant adjusted p-values (Figure-54). Metabolism, oxidation 
reduction process and other metabolic processes pathways were observed with significance like the results 









(Figure-54) Functional enrichment analysis was conducted using gProfiler on gene list comprised of genes that were significantly 
altered in expression according to the transcriptome data and matched with their respective proteins according to the proteome 
data. X-axis shows the databases the gene list was ran against and the y-axis shows the adjusted p-value. Detailed interactions are 







In addition, proteins that were only detected in the 20HE or vehicle treated group were converted to their gene 
names using uniport database and then the resulted gene lists were compared to the significantly over or under 
expressed genes from the transcriptome data. Out of the 70 proteins only detected in the 20HE treated group, 56 
were also detected in the transcriptome with significance (Figure-55). The gene list consisting of these 56 genes 
were then analysed on STRING for the functional enrichment analysis investigation. The same was done for the 
vehicle treated group which yielded 61 matched proteins to the transcriptome data (Figure-56). 
Additional analysis was conducted using FunRich version 3.1.3 which is a functional enrichment analysis software 
available online. An over view of some of the protein/gene lists created and used in the analysis are presented in 
(Figure-57) where the analysis was conducted using gene names from the transcriptome and protein accession 
numbers were converted to their respective gene names using UniProtKB (93). Interestingly, after converting 
proteins that were uniquely detected in either the placebo or 20HE group to their gene names it was shown that 
36 of proteins uniquely detected in either group originated from same genes (Table-26). Which may suggest post 


















(Figure-55) Functional enrichment analysis of proteins unique to the 20HE-treated group matched with 
significantly differentially expressed genes detected in the transcriptome data. Analysis and figure were 
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(Figure-56) Functional enrichment analysis of proteins unique to the vehicle-treated group matched with 
significantly differentially expressed genes detected in the transcriptome data. Analysis and figure was 
generated using STRING tool (91). 
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(Figure-57) Venn diagram of gene lists exported from the transcriptome and proteome analyses and uploaded 
to FuRich software. Protein accession numbers uniquely detected in either 20HE(Orange) or placebo (yellow) 
group were converted to their gene names and compared to significantly differentially expressed genes detected 
in the transcriptome (blue) and proteins that were significantly changed in abundance based on the proteomics 
























name and base pairs 
1 SPTAN1 Q13813  Name: SPTAN1-202 
Bp: 7889 
A0A0D9SF54 Name: SPTAN1-222 
Bp: 7812 
2 ETFA H0YLU7  Name: ETFA-215 
Bp:917 
P13804 Name: ETFA-202  
Bp: 1346 
3 GBE1 E9PGM4  Name: GBE1-205 
Bp: 2513 
Q04446 Name: GBE1-201  
Bp: 2941 
4 PAICS E9PBS1  Name: PAICS-006  
Bp: 1565 
P22234 Name: PAICS-201 
Bp: 3339 
5 CMPK1 Q5T0D2   Name: CMPK1-004 
Bp:1212 
P30085 Name: CMPK1-005 
Bp:950 
6 PARK7 Q99497 Name: PARK7-001 
Bp:1088 
K7ELW0 Name: PARK7-003 
Bp:795 
7 APEX1 G3V5Q1  Name: APEX1-016 
Bp:952 
P27695 Name: APEX1-013 
Bp: 671 
8 RPS9 B5MCT8 Name: RPS9-007 
Bp:944 
P46781 Name: RPS9-001 
Bp:772 
9 ATP6V1B2 H0YC04  Name: Not-found 
Bp: 
P21281 Name: ATP6V1B2-001 
Bp:2865 
10 GNB2 C9JIS1 Name: GNB2-010 
Bp:910 
P62879 Name: GNB2-006 
Bp:1641 
11 GSTO1 Q5TA02  Name: GSTO1-004 
Bp:829 
Q5TA01 Name: GSTO1-201 
Bp: 900 
12 MYL6 F8VPF3  Name: MYL6-214 
Bp: 411 
G8JLA2 Name: MYL6-201  
Bp:664  
13 GSTZ1 A0A0A0MR33 Name: Not-found 
Bp: 
G3V5T0 Name: GSTZ1-007 
Bp: 795 
14 LDHB A8MW50 Name: LDHB-004 
Bp:744 
P07195 Name: LDHB-002 
Bp: 1538 
15 RPL23A P62750  Name: RPL23A-001 
Bp:1562 
K7EMA7 Name: RPL23A-006 
Bp: 639 
 
(Table-26) Fifteen out of 36 genes that expressed different proteins in response to 20HE. Proteome data showed 
proteins only detected in either treatment groups and after converting the protein accession numbers to their 







Proteins accession number lists were used comparing unique proteins detected in the placebo group to proteins 
uniquely detected in the 20HE group. Functional enrichment analysis on biological processes (Figure-58). Cell 
growth and or maintenance pathway was represented by little over 15% in the 20HE treated cohort in contrast to 
the placebo group which was 3.33%. Protein metabolism and signal transduction pathways were also more 




(Figure-58) Protein lists uniquely detected in either 20HE or the placebo group were analysed using FunRich 
software v. 3.1.3 and few of the pathways enriched in each cohort is presented. In the 20HE group 25% of the 
genes only detected in this group were related to signal transduction and cell communication while almost 19% 








Another analysis was conducted comparing molecular function (Figure-59). Increased representation of catalytic 
and GTPase activity was observed in the placebo group compared to the 20HE group. While GTP activator activity 
was increased in the 20HE group. Proteins uniquely detected in either of the cohort (20HE or placebo treated) 
were also compared to the significantly differentially expressed genes from the transcriptome. Out of 59 proteins 
of the placebo group 58 were significantly differentially expressed in the transcriptome data while all 56 proteins 
were found also significant in the transcriptome data. After matching the proteins lists to the significantly 
expressed genes another functional enrichment analysis was conducted (Figure-60). 
 
 
(Figure-59) Functional enrichment analysis of proteins uniquely expressed in either the 20HE or placebo group. 










(Figure-60) Proteins uniquely expressed in either the 20HE or placebo treated cohorts were compared to their 
respective genes and those that were significant in the transcriptome data were included in this analysis. 













4.3 Validation of NOS3 expression 
Throughout the course of this study Nitric oxide synthase 3 (NOS3) through the different techniques of 
investigation was consistently found significantly overexpressed. This was observed in the human microarray 
analysis, in the transcriptome data and in the functional enrichment analysis conducted represented by the 
VEGFR-signalling pathway. To further validate this finding, 20HE-induced increase in NOS3 protein expression in 
Human Coronary Artery Endothelial Cells (HCAECs) was investigated. HCAECs were treated with varying 
concentrations of 20HE which resulted in dose-dependent increases in NOS3 protein expression in cells treated 
with 20HE compared with the untreated control. An  increase of 39%  was recorded in cells treated with 1nM and 
highest increase of 68 % was recorded in cells treated with 100nM of 20HE compared with untreated control 
(Figure-61).  qPCR data showed significant increases in NOS3 expression in response to increasing concentrations 


























(Figure-61) Dose dependent effect of 20HE on NOS3 expression in HCAECs. At the level of protein noticeable 



















(Figure-62) qPCR of NOS3 expression in HCAECs after treatment with different concentrations of 20HE. 
Significant increase in expression was observed in response to 1, 10, 100 nM and 1µM concentrations of 20HE 



























4.4 Discussion of results 
Human physiological effects 
The number of supplements containing ecdysteroids are increasing and often advertised either as natural steroids 
or in the form of their natural sources such as spinach, Suma root or quinoa. This prompts for further investigation 
of its effect in humans especially since its ergogenic effect appeals to a great portion of society. Physiological effect 
of 20HE in humans in-vivo as a supplement (Desire-X) that is readily available from online retailers was reported 
in this chapter. 
 
After the intervention with 20HE supplement an increase in body weight was observed that is attributed to 
increased muscle mass since the fat mass was reduced by ≈1 fold. Measures of blood pressure showed significant 
decrease in DBP which affected the calculated MAP to be reduced but did not reach significance. Blood chemistries 
were also recorded, and Creatinine was found to be significantly increased after the 20HE intervention p-value= 
0.03.   
Indices of aerobic fitness did not show any significant improvement (VO2max , vVO2  and MET). Significant decrease 
in MVV and RQ were recorded after the intervention with 20HE.  MVV (Maximum voluntary ventilation) is 
considered as an indication ventilatory function and RQ (respiratory quotient) value indicates the amount of 
energy used for metabolic processes and values of less than 1 indicate the use of protein and carbohydrates as a 
source of energy. MVV and RQ measurements were significantly reduced (p <0.01) after the intervention with 
20HE while in the placebo supplement group MVV was significantly reduced (p <0.01) and RQ was also reduced 
without statistical significance.   
 
Human in-vitro study on mitochondrial membrane potential (MMP) 
Mitochondrial membrane potential was investigated in-vitro in response to varying concentrations of 20HE. 
Significant increase in MMP was observed after overnight treatment of the cells with 20HE at concentration of 5 
& 10µM. No difference was observed after treatment with 1µM of 20HE. These experiments were conducted on 
preadipocytes and myoblasts and technical difficulties caused the inability to differentiate these cells to investigate 










The first omics approach was the proteome analysis which quantified the abundant proteins within the liver tissue 
of 20HE treated and placebo treated groups. Proteomics analysis method used looked at the total proteins without 
depletion of the most abundant proteins. It was reported that 99% of proteins extracted from blood sera 
comprised of only 22 proteins (95). Nonetheless, using quantification method allowed the comparison between 
the two groups where, out of 1664 proteins identified and quantified, 68 were uniquely detected in the placebo 
group and 70 were unique to the 20HE treated group. The second omics approach was the transcriptome analysis 
using RNA extracted from liver tissue of 20HE and placebo treated groups. Analysing the data on TAC 4.0 software 
presented 37 differentially expressed genes with significance (p-value≤ 0.05) which included significant decrease 
in the expression of a negative regulator of myogenesis (HES1).  
 
Omics approaches yield an overwhelming amount of data which can be challenging to analyse. Functional 
enrichment analysis allows the visualisation of these data in the context of their biological functions which can 
provide an indication of possible pathways of interest with ease. Functional enrichment analysis was conducted 
on both protein and gene lists extracted from the proteome and the transcriptome. Metabolism pathways were 
enriched in the proteome while few pathways were identified and explored including the VEGFA-VEGFR signalling 
pathway from the transcriptome data. Protein lists were then converted to their gene ID and the resulting gene 
lists from the proteome were analysed against the transcriptome data. This combined approach showed that the 
proteins that were uniquely detected in either group (20HE/placebo treated) were expressed from the similar 
genes.  
ranscriptome analysis can only provide an indication of significant upregulation of a gene and the actual protein 
that exerts the physiological function remains unknown until a combined method as conducted in this study is 
done. Transcripts undergo the process of alternative splicing which allows a single gene to produce different 
proteins or different isoforms of a protein. It’s been reported that the function of isoforms of the same protein 
translated from the same gene can cause conflicting effects in the context of cellular processes (96). According to 
another paper the different isoforms of a protein can exhibit striking difference in their interactome networks that 
it may appear to be originated from different genes (97). This shows the complexity of data analysis from the omics 
approach and how a combination of two or more platforms can provide more accurate indication of physiological 
functions. In addition, analysis complexity is expectedly great where protein IDs can be analysed against each other 





placebo vs transcriptome, unique 20HE proteins vs transcriptome and unique proteins vs transcriptome) and 
finally protein IDs converted to  
 
their gene names and compared against all the aforementioned analysis possibilities. In numbers, the following 
numbers of gene were matched to the transcriptome; 714 genes converted from total proteome, 56 genes from 
proteins unique to 20HE treated group and 61 genes from proteins unique to placebo treated group. Finally, after 
converting uniquely expressed genes in either group, 36 of these proteins originated from the same genes. 
 
Validation nos3 
Another finding that was further investigated, analysed and validated was the NOS3 overexpression in response 
to 20HE. Multiple techniques used during this study indicated the effect of 20HE on vasculature due to the 
significant overexpression of NOS3 in response to the pure form of the drug and as a supplement where 20HE also 
significantly affected the diastolic blood pressure. This was validated and confirmed in-vitro on human coronary 





































The global market for dietary supplements is estimated at be over $ 100 billion, which acts as an enormous 
incentive for manufacturers to try new and improved formulations continuously to ensure a competitive edge. 
Clinical trials on new preparations and personalisation of nutrition are just few of the recent trends within this 
industry (76). Though dietary supplements are intended to complement balanced diets, many consumers take a 
supplement without considering whether they actually need it, mainly because these supplements do not require 
prescriptions. Also, many of these products are actively advertised to the general population. Ergogenic effects of 
certain supplements appeal to a general cohort of consumers, while performance enhancing substances appeal 
especially to athletes, both recreational and elite. In the professional competitive sports context, dietary 
supplementation has increased the threats of inadvertent doping and also the risks to health. Many reports 
dispute the need or even the effectiveness of dietary supplements in performance enhancement, and, actually 
propose that it can, far more safely and effectively, be replaced with a suitably balanced diet, designed specifically 
for the nutritional demands before, during and after exercise, which could provide the required nutrition of the 
body when needed (98). It is understandable to recognise the pressure on elite athletes to enhance their 
performance, even marginally, which explains the “culture of additivity” (98). This has led to increased supplement 
intake among athletes, where good supplementation is linked to enhanced performance. An increasingly affluent 
and image conscious young population are also very susceptible to the lure of the quick fixes offered by these 
supplements. 
5.1 Discussion of results. As discussed in chapter 1, the labels on supplements do not necessarily reflect their 
actual contents, and this was supported by the results of this study, where around 69% of the obtained 
supplements that claimed to contain 20HE had unquantifiable or undetectable amounts of the ecdysteroid . These 
findings have been confirmed by another recent study on supplement-derived 20HE (99), which showed that the 
concentration of 20HE in various supplements can vary enormously. Mostly, the concentrations specified on the 
labels were much higher than those obtained by analysis (99). This may be because reference materials and 
standards are only available for a few ecdysteroids from reputable suppliers, such as the LGC Group and Sigma 
Chemical Company, for 20HE, Ponisterone A and Muristerone. Without these calibrants and quality control 
compounds it is not possible to set up specific assays or even test for cross-reactivity, especially for the more 
potent anabolic species, such as Turkerterone (55). A more accurate reporting of concentrations and the specific 
ecdysteroid on the label is imperative in sports supplements, since inadvertent doping cases is still reported as 
substance abuse.  
The investigation of these supplements after in vivo ingestion is also crucial and the use of the uPA +/+ SCID mouse 





be utilised for pharmacokinetic studies and analysis of the parent compound and its metabolites as biomarkers of 
use. However, it has to be recognised that this murine model is not without its limitations, such as the inability to 
investigate whole body physiology in these immunocompromised mice and the irrelevance of such an 
investigation if carried out, as the liver is the only humanised part of the animal. In addition, using this model 
provides only a limited time of exposure to the drug, thus does not lend itself to the investigation of chronic 
effects, as, for ethical reasons these animals cannot be maintained for more than 5 days. It is well documented 
that athletes consume supplements for long durations and this model cannot reflect that. On the other hand, 
excretion data of 20HE analysed from the animal model was confirmed and extended by the human excretion 
study, where 20HE remained detectable, at higher doses, for up to 48 hours after ingestion, which is an important 
finding in the context of doping control, since 20HE was added to the WADA monitoring list in October 2019. As 
it is likely that much higher doses are used by athletes because of their anabolic effects (66), the current data 
suggest that the detection window may be extended beyond 48 hours.   
Ecdysteroids appeal to its consumers due to their reported anabolic effects, that include the reduction of fat mass 
and increased muscle mass, which was also observed in this study but did not reach statistical significant, perhaps 
due to the lower doses used here. A major finding in the physiological studies in the human volunteers was the 
reduction in diastolic blood pressure. How and if this may affect blood flow needs further investigation. 
Results from the uPA +/+ mice (liver) and human studies (peripheral blood cells) showed a significant upregulation 
of the NOS3 gene, which encodes for endothelial Nitric Oxide Synthase (eNOS) enzyme (chapters 3 and 4). This 
was later confirmed in-vitro using human coronary artery endothelial cells (HCAECs, chapter 4). Nitric oxide is a 
known potent vasodilator aiding in providing adequate blood supply, which is imperative during physical activity 
(100).  While this vasodilatory effect may attract professional athletes to ensure adequate blood supply during 
competition it is important to note that literature showed that these effects of 20HE are not targeted, meaning 
that neither the vasodilatory effect nor the anabolic effects are specific to skeletal muscle (54). Therefore, 
increased blood flow at rest or in other organs, may not allow a directed response during exercise aimed 
specifically at increased skeletal muscle blood flow, which may actually hinder performance. In addition, while 
20HE may increase blood flow due to this vasodilatory effect, it has actually significantly reduced red blood cell 
(RBC) count (p= 0.01), which is another crucial parameter for oxygen delivery during performance of sport, which 
is why many athletes choose to undergo homologues or autologous blood transfusion, in order to increase their 
red cell count during competition (101).  
Its effects on mitochondrial membrane potential was significant indicating higher production of ATP. Although 





nonetheless aerobic fitness was also improved in-vivo in humans after 20HE intervention. This finding is very 
relevant in competitive sports, where any marginal improvement in performance is sought. One oversight while 
investigating aerobic fitness was the inability to calculate the aerobic threshold or ventilation threshold (AT) which 
is considered as a measure of fitness. In brief, a basic response to exercise is ventilation which increases linearly 
as the intensity of exercise and oxygen consumption are increased (aerobic metabolism) up to a threshold after 
which anaerobic metabolism is induced. AT the highest intensity an individual can maintain for a relatively long 
period of time without fatigue or build-up of lactic acid that may happen when AT is exceeded. It is measured as 
VCO2/VO2 and shall be included in future studies measuring aerobic fitness (25).   Other improvements included 
blood glucose and increased healthy cholesterol and decreased LDL cholesterol. 
Another interesting finding from the transcriptome studies was the downregulation of CYP17A1 in the 20HE 
treated liver. The CYP17A1 gene codes for making a protein belonging to the cytochrome P450 enzyme family. 
Similar to other cytochrome P450 enzymes, CYP17A1 regulates the synthesis of steroid hormones, such as 
testosterone and oestrogen, as well as the mineralocorticoids and glucocorticoids. The CYP17A1 enzyme catalyzes 
two key reactions, one associated with 17 alpha(α)-hydroxylase activity, converting pregnenalone to 17-
hydroxypregnenolone and progesterone to 17-hydroxyprogesterone (102), and the other is its 17,20-lyase 
activity, which converts 17-hydroxypregnenolone to dehydroepiandrosterone (102; DHEA). This reaction is a rate 
limiting step in the production of sex hormones. How, and if, this might be a role of 20HE, leading to alterations 
in levels of hormones such as testosterone is as yet unclear. It has been shown that CYP17A1 is highly expressed 
in over 50% of human prostate carcinomas, perhaps pointing to a role for it in intracellular androgen synthesis by 
cancer cells (103). Abiraterone, an FDA approved CYP17A1 inhibitor, has been reported to block nuclear 
accumulation of AR (104), but, whether this can be mimicked by 20HE has not been investigated, either in vitro or 
in vivo.  
 
5.2 Limitations of the studies. 
It is well understood that each study comes with its own set of limitations and in this study the limitations with 
regards to the use of the uPA +/+ SCID mouse model to investigate human hepatic metabolites were briefly 
discussed where the animals can only remain viable for up to 5 days, constricting any investigation to immediate 
effects only, without the ability to study the chronic effects on the liver metabolism and liver tissue. Systemic 
markers, effects on other organs, such as the adipose tissue and skeletal muscle, as well as whole body 





humanised and therefore information acquired from such investigations would be reliable, due to the nature of 
the animals.  
The human in-vivo investigations used 20HE supplementation, which was only one of the constituents of the 
supplement, rather than the pure form of the drug. This is a limitation as the other components may alter the way 
20HE is absorbed or works. Therefore, while using supplement-derived 20HE may have allowed the ethical 
investigation of the ecdysteroid in humans in-vivo, that some of the effects seen may have been caused by other 
constituents of the supplement, at least in part or in conjunction with 20HE, cannot be ruled out. This is especially 
so since the placebo supplement used was chosen only for its lack of detectable quantity of any ecdysteroid, and 
not a true placebo where its constituents are identical to the test supplement, but only lacking the drug of interest.  
The number of volunteers in the study were low. This was because of a high fall out rate and low compliance. As 
there was a need to recruit recreational athletes with a good level of aerobic fitness, so as to be of at least some 
relevance to the elite athletes, this posed a limiting factor to the numbers of volunteers identified. Therefore, this 
can only be viewed as a pilot study that needs to be extended and confirmed in larger numbers. In addition, only 
clinic blood pressure was recorded, and as the reduction in diastolic blood pressure was an interesting finding, 
this needs to be repeated with more precise techniques.     
In-vitro investigation of mitochondrial membrane potential was conducted using a single wavelength fluorescence 
measurement where the reduction in the of the emission intensity may have resulted from dye leakage or 
reduction of cell number due to toxicity and not necessarily an alteration of membrane potential per se. 
5.3 Future research. 
Many recreational and elite athletes may be using ecdysteroids due to their anabolic effects, making grounds for 
future investigation on the prevalence of ecdysteroids consumption among athletes. It would be possible to 
investigate this retrospectively using the methods developed in this study. The WADA accredited anti-doping 
laboratories collect 2 urine samples (A & B samples) on and off competition from competing athletes. The A 
sample is analysed to detect any known doping agent using various established methods. Once the results are 
reported as being negative the B samples are stored for only 3 months before being discarded. A future study 
could utilise these B samples, that were reported negative for current WADA prohibited substance, for this 
retrospective study to calculate prevalence of use. This is possible because all competing athletes have provided, 





The induction of NOS3 by 20HE needs to be investigated further in peripheral blood cells and skeletal muscle 
biopsies from trained athletes at rest and after training both acutely and over a period of time, along with more 
detailed measures of blood pressure and flow.  
The inhibition of the expression of CYP17A1 by 20HE and its putative effect on systemic and tissue levels of 
steroids, such as oestrogen, progesterone, DHEA and testosterone needs to be investigated. There is some indirect 
evidence that ecdysteroids may be associated with steroid hormone disruption (63). This offers scope for 20HE 
beyond sport, especially in the treatment of cancers, such as prostate and breast.  
Key experiments to follow-on the findings include: 
• Further investigation on the physiological effects of supplement derived 20HE in humans in-vivo with 
higher numbers and using true placebo supplement spiked with 20HE 
• Confirmatory and addition investigation of 20HE effects on mitochondrial respiration using Seahorse XF 
analyzer to test mitochondrial function in addition to oxygen consumption method.  
• In-depth analysis of the differential effects caused by 20HE from the proteome and transcriptome data 
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World Anti-Doping Agency (WADA) publishes a list of substances as part of their monitoring program 





The following substances are placed on the 2020 Monitoring Program: 
 









In- and Out-of-Competition: ecdysterone 
In- and Out-of-Competition: any combination of beta-2-agonists In- 
and Out-of-Competition 
 
In-Competition only: bupropion, caffeine, nicotine, phenylephrine, 
phenylpropanolamine, pipradrol and synephrine 
In-Competition only: codeine, hydrocodone and tramadol In-
Competition (by routes of administration other than oral, 
intravenous, intramuscular or rectal) and Out-of-Competition (all 
routes of administration) 
 
*The World Anti-Doping Code (Article 4.5) states: “WADA, in consultation with Signatories and 
governments, shall establish a monitoring program regarding substances which are not on the 
Prohibited List, but which WADA wishes to monitor in order to detect patterns of misuse in sport. ” 
 





Qiagen RT2 profiler arrays were used to investigate phase I drug metabolism enzymes. They included 
84 key genes involved in the process in addition to housekeeping genes for normalisation. 
 
Phase 1 drug metabolising panel. a) Human PCR Array. RT² Profiler™ PCR Array Human Drug 
Metabolism: Phase I Enzymes (PAHS-068Z) – Qiagen and b) Mouse PCR Array. RT² Profiler™ PCR 





















Human in-vivo studies investigating the human physiological effects of 20HE were conducted. 
















Criteria for Description 
Inclusion  Male, Adult (aged ≥ 21 years), Recreational athletes, BMI  ≤ 30 Kg/ m2, of 
Arab ethnicity 
Exclusion  Diabetes, Hypertension, taking dietary supplements in the 3 months 
preceding the study, Current treatment with warfarin, Connective tissue 
disease or other inflammatory conditions likely to affect cytokine levels, 
Malignancy or other terminal illness, Immune compromised subjects, 
Autoimmune disease, Chronic infection, Substance abuse or other causes 






Consent form signed by the recruited volunteers for the human in-vivo study. 
Participant’s Statement 
Documentation of Permission 
Principal investigator   
As a representative of this study, I have explained the purpose, the procedures, the possible benefits and risks 
that are involved in this research study.  Any questions that have been raised have been answered to the 
individual’s satisfaction.                                                                                         
 
Signature of Person Obtaining Consent  Date of Signature 
Research  Participant / Authorized  Persons  
 
I, the undersigned have been informed about this study’s purpose, procedures, possible benefits and risks, and 
I have received a copy of this consent.  I have been given the opportunity to ask questions before I sign, and I 
have been told that I can ask other questions at any time.  I voluntarily agree to be in this study.  I am free to 
stop being in the study at any time without need to justify my decision and if I stop being in the study I 
understand it will not in any way affect the benefits I normally have. I agree to cooperate with (name of principal 
investigator) and the research staff and to tell them immediately if I experience any unexpected or unusual 
symptoms. 
 
Participant’s Signature  Date of Signature 
   
Signature of Witness  Date of Signature 
   
Signature of Legally Authorized Representative (When Appropriate)  Date of Signature 
   








Functional enrichment analysis conducted on the gene list exported from the Transcriptome and proteome 
data. genes that were significantly altered in expression according to the transcriptome data and matched 
with their respective proteins according to the proteome data. X-axis shows the databases the gene list was 
ran against and the y-axis shows the adjusted p-value. Detailed interactions are presented in the table below. 
  
 
 
 
 
 
